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ABSTRACT 
 
ELLA NKHOMA:  Malaria and Pregnancy Outcomes in an Area of High HIV and Glucose-
6- phosphate dehydrogenase deficiency prevalence (Under the direction of Steven Meshnick) 
 
 
HIV and G6PD deficiency are part of a milieu of population-level biological factors in which 
pregnancies occur in malaria-endemic areas.    In this research we examine the effect of HIV 
infection and malaria parasitemia on pregnancy outcomes, the relationship between HIV 
infection and risk, frequency, and severity of maternal parasitemia, and the effect of G6PD 
deficiency on parasitemia risk and pregnancy outcomes.  
 
Between 2005 and 2006, we followed pregnant women attending two antenatal care clinics in 
southern Malawi from the second trimester of gestation until delivery.  HIV was associated 
with increased risk of LBW (adjusted prevalence ratio, PRadj=3.08, 95% confidence interval, 
CI, = 1.40, 6.79).  Placental parasitemia was associated with an elevated risk of LBW 
(PRadj=1.79, 95% CI = 0.83, 3.84), as was having ≥3 episodes of peripheral parasitemia 
during follow-up (PRadj=2.68, 95% CI = 1.06, 6.79).  
 
HIV was not associated with increased risk of parasitemia among primigravidae over follow-
up (RR=1.0, 95% CI: 0.4, 2.8). Among multigravidae, the risk of parasitemia over follow-up 
among HIV-infected women was 2.2 times (95% CI: 1.5, 3.2) that of HIV-uninfected 
women.  Further, the odds of having ≥3 episodes of parasitemia among HIV-infected 
multigravidae were 4.8 (95% CI: 2.1, 10.9) times that of HIV-uninfected multigravidae.  
 iv 
 
 
 
Among both primigravidae and multigravidae, placental parasite density among HIV-
infected women was on average 3.6 (95% CI: 1.8, 7.2) times as high as among HIV-
uninfected women. 
 
G6PD A- primigravidae were as likely to have placental parasitemia as G6PD-normal 
primigravidae (PR=1.0, 95% confidence interval (CI): 0.7, 1.3). Among multigravid G6PD 
A- carriers, the prevalence of placental parasitemia was 0.9 (95% CI: 0.8, 1.0) times that of 
G6PD-normal women. Further, their placental parasite density was on average 0.22 times 
that of G6PD-normal multigravidae.  Among primigravidae, G6PD A- carriers had 1.7 (95% 
CI: 1.0, 2.9) times the average risk of maternal anemia over follow-up when compared to 
G6PD-normal women. Across gravidities, G6PD deficiency was associated with an increased 
risk of low birth weight (PR=2.5, 95% CI: 1.2, 5.2).   Understanding the contribution of these 
different coexistent factors should aid in the design of effective interventions to improve 
maternal and infant health in malaria-endemic areas. 
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CHAPTER ONE - SPECIFIC AIMS 
 
In malaria endemic areas, pregnant women are at high risk of morbidity from malaria.  
Malaria during pregnancy can affect the health of the mother through maternal anemia and 
the health of the infant by contributing to low birth weight [1]. HIV infection has also been 
associated with low birth weight [2]. Furthermore, being infected with HIV can increase the 
risk of malaria[3].  In many malaria endemic areas, however, the prevalence of glucose-6 
phosphate dehydrogenase (G6PD) deficiency, an enzymopathy hypothesized to protect 
against clinical malaria, is relatively high[4].  Therefore, in areas such as Eastern Africa, 
where the prevalence of both HIV and G6PD deficiency is high, there can be a push and pull 
of factors influencing not only malaria risk, but also the risk of adverse pregnancy outcomes. 
The objective of this study is to determine the effects of malaria, HIV infection and 
glucose-6-phosphate dehydrogenase (G6PD) deficiency on maternal anemia and low birth 
weight in a cohort of women delivering at the Mpemba and Madziabango clinics in Blantyre 
District, Malawi.  Between 2005 and 2006, data were collected on HIV seropositivity, 
placental parasitemia, hemoglobin levels, and birth weight.  Additionally, blood samples 
collected from the women were genotyped for carriage of the A- allele, corresponding to the 
mutation that confers G6PD deficiency among sub-Saharan African populations. 
Malaria is a tremendous public health challenge in Malawi, with over 2 million 
reported cases each year out of a population of 12 million people[5].  The entire population 
of Malawi is at risk of malaria, with 97% living in malaria endemic areas and 3% living in 
areas subject to malaria epidemics. Each year in Malawi, there are approximately 500,000 
  2
 
 
pregnancies, all at risk of malaria [5].  Given this widespread risk and the deleterious effects 
of malaria during pregnancy, intermittent presumptive therapy (IPT) in the form of 
sulfadoxine-pyrimethamine (SP) is provided to pregnant women through antenatal care 
clinics. However, recent evidence suggests that SP treatment failure due to parasite resistance 
is increasing rapidly in Malawi as in other parts of Eastern Africa [6].  
 As SP treatment failure becomes more frequent, other antimalarial drugs will need to 
be considered for IPT.  Uptake of certain classes of antimalarial drugs can elicit acute 
hemolysis in G6PD deficient individuals [7].  Given this adverse interaction, it is very 
important to understand the distribution of this enzyme deficiency and its contribution to 
malaria risk.  HIV also represents another major contribution to malaria risk in sub-Saharan 
African countries.  Malawi, again like many countries in Eastern Africa, has not been 
immune to the HIV/AIDS epidemic with over 12% of women visiting antenatal clinics 
infected [8].  Understanding HIV infection and G6PD deficiency as elements of the disease 
context of malaria will enable public health policymakers to more comprehensively address 
adverse pregnancy outcomes in Malawi. 
 
Specific Aim 1.  What is the effect of malaria and HIV infection during pregnancy on 
maternal anemia and birth weight? 
 
• Objectives: 
1. To determine the separate effects of HIV infection and malaria on maternal 
anemia and low birth weight. 
2. To assess interaction between the effects HIV infection and malaria on 
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maternal anemia and low birth weight. 
Specific Aim 2.  What is the effect of HIV infection on parasitemia risk at enrollment, during 
follow-up and at delivery? 
 
• Objectives: 
1. To describe the pattern of parasitemia risk over the second and third trimester. 
2. To estimate the effect of HIV on the risk of parasitemia at enrollment, over 
the follow-up period and at delivery. 
3. To determine the relationship between HIV infection and frequency and 
severity of parasitemia at delivery. 
 
Specific Aim 3.  What is the relationship between carriage of the G6PD A- allele and 
parasitemia and anemia among pregnant women? 
• Objectives: 
 
1. To estimate the prevalence of carriers of the G6PD A- allele among a cohort of 
pregnant women in Southern Malawi. 
2. To determine if the risk of peripheral parasitemia during pregnancy and 
placental parasitemia at delivery among G6PD deficient women is different 
from the risk among G6PD-normal pregnant women. 
3. To determine if the risk of low birth weight of infants born to G6PD deficient 
women is different from that of infants born to G6PD-normal pregnant women. 
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CHAPTER TWO - BACKGROUND AND SIGNIFICANCE 
 
Each year, 20 – 50 million women become pregnant in malaria-endemic areas [1-3].  
In these women, exposure to and subsequent infection with malarial parasites, especially 
Plasmodium falciparum, can have remarkable implications during the course of pregnancy 
and may affect birth outcomes, with an estimated 75,000 – 200,000 infant deaths per year 
associated with malaria infection during pregnancy [3].   
In Malawi, like in many countries in Southern Africa, the national prevalence of HIV 
infection among antenatal care clinics is high, estimated at 12% [4].  HIV infection among 
pregnant women is associated with adverse pregnancy outcomes including low birth weight 
and infant mortality [5]. HIV infection has also been found to increase the risk of malaria 
among pregnant women [6].   
Glucose-6-phosphate dehydrogenase deficiency is thought to protect against clinical 
malaria among people living in endemic areas, by impeding the parasites ability to establish 
infection.  Some studies have confirmed this relationship among children and non-pregnant 
adults, while others have failed to find an association [7-9].  Only one cross-sectional study 
in the literature has examined this relationship among pregnant women [10].   
The primary goals of the proposed study are to evaluate the relationship between 
malaria and HIV infection on pregnancy outcomes and to determine the effect of G6PD 
deficiency on maternal anemia and malaria. 
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Malaria and pregnancy 
 
The unusual relationship between pregnancy and malaria infection has been described 
for more than 60 years [3].  While the immune status of women to malaria generally mirrors 
that of men, pregnant women, especially primigravidae, are usually at much increased risk of 
malaria infection than both males and their non-pregnant female counterparts [11, 12].  At 
first, this was thought to be caused through the immuno-suppression triggered by pregnancy-
associated hormones and proteins.  This immuno-suppression would then increase the 
mother’s susceptibility to various infections, including malaria.  However, it was noted that 
while mean gamma-immunoglobulin (IgG) concentrations decrease with the progression of 
the pregnancy, with the lowest titers in the third trimester of pregnancy,  the risk of maternal 
malaria infection, however, is highest in the first trimester, and lowest in the third trimester 
[11]. 
The more likely hypothesis, however, is that “pregnancy establishes within an 
otherwise effectively immune host an extremely vascular organ that shields parasite[s] from 
destruction by extra-uterine immune effector mechanisms” [11].  This hypothesis was 
originally posited in 1984, but there was no supporting evidence until recently.  A number of 
recent studies have demonstrated that pregnant women are infected by particular variants of 
P. falciparum that  have special affinity for  the chondroitin sulphate A (CSA) receptor 
expressed on the surface of placental cells[13, 14].    These variants do not infect non-
pregnant hosts and differ in their ability to evade immune response.  Therefore, even if a 
woman was previously immune, the introduction of this novel variant renders her highly 
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susceptible to infection, especially during the first pregnancy.  With successive pregnancies, 
the woman gradually develops immunity to this new parasite population [11, 15]. 
The condition described above is known as placental malaria (PM) and has adverse 
consequences for the mother and the fetus.  During placental malaria, the parasites are 
sequestered in the placenta, but are not present in the rest of the body. Thus, blood smears, 
the usual mode of malaria diagnosis, will often give false negative results [16].  In contrast, 
among non-pregnant adults, a negative blood smear is more likely to indicate the lack of 
infection [12].  Among pregnant women, histological examination of the placenta is the most 
sensitive method of malaria detection [17-19]. 
 
Malarial anemia and pregnancy 
 
Placental malaria has been associated with spontaneous abortion, stillbirth, low birth 
weight (LBW), intrauterine growth retardation (IUGR), prematurity, and severe maternal 
anemia.  Severe maternal anemia, defined as hemoglobin <7g/dL, is a major effect of 
maternal malaria in endemic regions [11, 12, 16].  A number of cross-sectional surveys have 
found that the prevalence of severe anemia was greater in women infected with malaria when 
compared to those without malaria [2].  
In the systematic review by Guyatt & Snow, the prevalence of severe anemia was 
higher in primigravidae when compared to multigravidae [2].  The median prevalence of 
severe anemia among primigravidae for 18 studies was 11.3% (interquartile range (IQR): 
7.0-19.5%) with a prevalence of 8.2% (IQR: 4.5-10.3%) among all gravidities  [17]. In a 
study, conducted in Ethiopia, placental parasitemia was associated with anemia among both 
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pregnant women living in stable transmission areas (relative risk (RR) = 2.0, p<.001) and 
women in unstable transmission areas (RR=4.4, p<0.001) [20].  Another study conducted in 
Tanzania, found that anemia among pregnant women was associated with the rainy season 
(high malaria transmission period, odds ratio (OR) = 6.02, p<0.001)[21].  Yet another cross-
sectional survey, conducted in Mali reported increased risk of anemia during the rainy season 
(OR = 1.93, 95%CI 1.10, 3.39, in rural areas, OR = 3.55, 95% CI: 1.46, 8.62) [22]. 
In a prospective intervention study conducted in Malawi, women were followed 
during the course of pregnancy and monitored for malaria status. At delivery, blood from the 
placenta was examined for the presence of parasites. Placental examination was associated 
with an increase in the number of cases of maternal malaria of 12%.  In associations of 
maternal malaria with LBW, the authors reported increased risk with both maternal malaria 
(minus placental malaria, OR=1.84, 95%CI: 1.26, 2.68) and placental malaria (OR=2.57, 
95%CI 1.77, 3.72).  Similarly, for associations with anemia, there was increased risk of 
anemia among women with maternal malaria (minus placenta malaria, OR=1.85, 95% CI: 
1.45, 2.36) and placental malaria (2.0, 95%CI: 1.5, 2.7) [19].   
Severe maternal anemia has various consequences for the mother and the fetus.  
Anemia resulting from placental parasitization is often asymptomatic and so may be 
overlooked until it becomes very severe [16]. Severe anemia may result in maternal heart 
failure and decrease the ability of mothers to endure blood loss associated with delivery. This 
increases the mother’s risk for blood transfusion and maternal death [23].In the fetus, 
maternal anemia is associated with LBW. This is thought to be mediated through the reduced 
oxygen transport which contributes to IUGR. Furthermore, the chronically inflamed state of 
the placenta is thought to hasten labor, thus resulting in prematurity.  All of these three 
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conditions are associated with infant mortality, especially in developing countries [2, 23]. 
  
HIV and pregnancy 
 
HIV infection in pregnancy has been associated with spontaneous abortion, stillbirth, 
infant mortality, growth retardation, low birth weight and preterm delivery [5].  A systematic 
review/meta-analysis of studies published before 1997 from different countries on HIV 
infection and adverse birth outcomes reported that HIV infection results in a four-fold 
increase in infant mortality (Peto OR = 3.69; 95% CI: 3.03, 4.49; 9 studies). Additionally, 
HIV infection was found to increase the risk of low birth weight (Peto OR = 2.09; 95%CI: 
1.86, 2.35; 17 studies).  The standard mean difference in birth weight was reported as -0.342 
(95%CI: -0.421, -0.262; 7 studies).    In a study conducted in Kigali, Rwanda, HIV-positive 
women were 1.8 (95%CI: 1.1-2.9) times as likely to deliver low birth weight babies when 
compared to HIV-negative women [24].   The relationship between HIV infection and 
maternal anemia is unclear.  In the study conducted in Rwanda, no relationship was observed 
between HIV infection and anemia (defined as Hb <10g/dL) [24].  However, in a study 
conducted in Kenya, HIV-positive pregnant women were found to have 1.7 (95%CI: 1.3 -
2.0) times the risk of anemia (defined as Hb < 11g/gL) [25].  Another study conducted in 
Kenya reported that being HIV seropositive increased the odds of anemia (defined as <8g/dL 
OR=2.0, 95%CI: 1.2-3.3) among primigravidae [26]. 
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HIV, malaria, and pregnancy 
 
According to recent evidence, not only does HIV infection increase the risk of 
malaria, the infection may also interact with malaria to cause adverse pregnancy outcomes 
[6, 27].  Among pregnant women, HIV infection increases the risk of peripheral and 
placental malaria, high parasite density, fever and severe anemia [27].  Generally, among 
pregnant women living in malaria endemic areas, the risk of malaria decreases with 
increasing gravidity.  However, HIV, even without development to AIDS, seems to interfere 
with the development of immunity that is normally correlated with increasing gravidity [27].  
For example, in a study conducted in Kenya, the relative risk for parasitemia in the third 
trimester was similar among primigravidae, secundagravidae, and multigravidae (RR=2.40, 
95% CI 1.64-3.53; RR=2.54, 95% CI 1.32-4.86; 2.66, 95% CI 1.10-6.43).  Similar results 
were also observed for symptomatic clinical malaria across all three categories of gravidity 
[28]. Thus HIV infection disrupts the typical relationship between gravidity and malaria risk. 
The increased risk in malaria coupled with the effects of HIV infection may interact 
to result in adverse pregnancy outcomes more pronounced than those that would be expected 
with HIV infection or malaria alone.  In a study conducted in Malawi, the odds of neonatal 
mortality among infants with low birth weight born to mothers with placental malaria was 
2.0 (95% CI: 0.9 – 4.6).  Among pregnant women with placental malaria and HIV infection, 
the odds of neonatal mortality among low birth weight infants was 8.98 (95% CI: 3.1-25.9) 
[29].  Another study conducted in Tanzania reported that among pregnant women infected 
with HIV, any parasitemia at the first visit was associated with an increased risk of low birth 
weight (defined as <2500 g, RRadjusted = 2.66, p=0.01) [30]. In a study conducted in Kenya, 
  11
 
 
the odds of low birth weight among primigravidae with malaria were 2.3 (95% CI 1.3-4.2) 
times that of aparasitemic primigravidae. However, among primigravidae infected with both 
HIV and malaria, the odds of low birth weight were 3.5 (1.7-7.1) times that of primigravidae 
with neither infection [26]. Similar results were reported for maternal anemia.  Multigravidae 
infected with both HIV and malaria had 3.2(95% CI: 1.7 – 6.2) times the odds of anemia 
(defined as Hb<8g/dL) as multigravidae with HIV only.  In the same way, multigravidae with 
dual infection had 2.8 (95% CI:1.3-6.0) times the odds of maternal anemia as multigravidae 
with malaria only.  This relationship was observed among primigravidae as well with the 
reference as parasitemic primigravidae [26]. 
 
G6PD deficiency 
 
Glucose-6-phosphate deficiency is the most prevalent enzyme deficiency with over 
300 million people affected worldwide [31].   The enzyme catalyzes the first rate-
determining step in the pentose phosphate pathway that forms part of glycolysis.  In the 
erythrocyte, the conversion of glucose-6-phosphate into 6-phosphogluconolactone, catalyzed 
by G6PD is a very important source for the production of NADPH (hydrogenated 
nicotinamide).  This compound acts by reducing glutathione and stabilizing catalase, two 
compounds that have crucial anti-oxidant properties in the red blood cell. Thus, G6PD 
activity helps the erythrocyte to withstand oxidative stress [32]. 
The gene encoding for G6PD is found on the long arm of the X chromosome (Xq28), 
and consists of 13 axons with a length of 18kb [33].  The G6PD locus is thought to be one of 
the most polymorphic loci among humans with almost 400 allelic variants reported [32].  The 
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variants are subdivided into five classes based on level of deficiency, with Class 1 
characterized by severe deficiency resulting in chronic non-spherocytic anemia ranging to 
Class 5 with greater than 150% of normal activity [33].  The variants encountered in sub-
Saharan Africa fall in Class III (moderate deficiency, 10-60% of normal activity) and Class 
IV (approaching normal to normal activity, (60-150% of normal activity).  The main allelic 
variants found in sub-Saharan Africa are G6PD B (wild type or normal variant), A (80% 
activity), and the deficient variant A- (12% activity) [33].   
The global prevalence of G6PD deficiency is most pronounced in Africa, 
Mediterranean Europe, South-East Asia, Latin America, and among the black population and 
the populations of Mediterranean origin in the United States [34].  In sub-Saharan Africa, the 
prevalence of the G6PD A- type is estimated to range between 0 – 25%, with an average of 
20% [33].  Some specific studies have reported prevalences of 22% (Gabon), 24% (Malawi), 
and up to 28% (Nigeria) [9, 35, 36].  In Democratic Republic of Congo, the prevalence 
estimate is 22% [37].  The high prevalence of G6PD deficiency in sub-Saharan Africa and 
the global geographic distribution of G6PD deficiency can be super-posed onto that of 
endemic malaria. This has led to the hypothesis that the enzyme deficiency may confer 
protection against malaria [33]. 
 
G6PD deficiency and malaria 
 
The hypothesis that G6PD deficiency may confer protection against malaria has been 
tested through observational studies and also in vitro.  In vitro studies indicate that the 
biological mechanism behind a possible protective effect may take place in two ways.   The 
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two main mechanisms though to be at play are ‘abortive’ infection and ‘suicidal’ infection.  
In ‘abortive’ infection, because of the red blood cell’s inability to counter oxidative stress, 
there is an accumulation of various toxic substances, such as hemozoin from the malaria 
parasites. This accumulation then impairs parasite development and multiplication.  Some in 
vitro studies also point to ‘suicidal’ infection. This can occur in two ways. One is through the 
formation of methemoglobin and release of ferriheme after exposure to oxidant stress. This 
then leads to the premature lysis of the erythrocyte.  The second way is through peroxidation 
of lipids in the membrane of the cell. This is thought to lead to increased phagocytosis of 
infected cells with deficient variants of G6PD [33, 38]. 
Evidence concerning the role of G6PD deficiency on malaria has also come from 
observational studies.  In a case-control study of over 2,000 children conducted in Kenya and 
the Gambia, G6PD deficiency, defined as carriage of the A- allele was found to be highly 
protective for mild malaria (odd ratio (OR) = 0.59, 95% confidence interval (CI): 0.36 – 
0.94) and severe malaria (OR = 0.54, 95%CI: 0.34-0.84) [8].   A cross-sectional study 
conducted among 271 children in Gabon found that the prevalence of asymptomatic 
parasitemia among A- heterozygous females was lower than among wild type females (p = 
0.03).  No association was observed among male hemizygotes [39].  Another study in Gabon 
employing a longitudinal design among 300 children found a protective effect among 
females carrying A- allele for clinical malaria (p=0.026), but did not find a difference in 
parasitemia. Similar to the other study conducted in Gabon, no effect was observed among 
male hemizygotes [9]. 
For the purposes of this proposal, discussion has been limited to G6PD deficiency 
from the A- variants found in sub-Saharan Africa. However, there are studies from other 
  14
 
 
regions of the world which have explored the G6PD deficiency and malaria hypothesis 
[8][33].  Although several studies have been conducted on children and some on adults, few 
studies have looked specifically at pregnant women.  Even though the relationship between 
malarial and pregnancy has been recognized for some time, it is only recently that we have 
come to understand that the pregnant woman, especially when experiencing first pregnancy, 
represents a naïve host to a particular strain of P. falciparum.  Furthermore, even with 
subsequent pregnancies, women in endemic areas are not constantly exposed to the strain as 
they are strains which infect the periphery circulation.  In the literature, there is one cross-
sectional study conducted among 529 pregnant women in Ghana [10]. 
In the Mockenhaupt et al study, carriage of the A- allele was found to be protective 
for parasitemia among all women (p=0.04).  When stratified by gravidity, the association was 
observed only among multigravidae (p=0.01). When stratified by trimester, an association 
was observed only among women in their third trimester of pregnancy (p=0.007).  Similar 
results were observed for anemia which was found to be more frequent among infected 
women compared to non-infected women (p<0.0001) and more frequent among 
primigravidae than multigravidae (p<0.0001) [10]. Although this study contributes much to 
the current literature, it is subject to several limitations. One, since a cross-sectional study 
was employed, risks of parasitemia and malaria were not directly estimable. Secondly, 
although the outcomes of parasitemia and anemia were very common in this study, the 
authors relied on logistic regression to obtain effect estimates. Another limitation was that 
exposure to G6PD deficiency was defined as carriage of the A- allele. However, it has been 
shown that heterozygous carriers of the allele can have normal activity since the alleles are 
additive for the phenotype [36].  Thus, without measuring G6PD activity, there is potential 
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for misclassification error that is differential according to outcome.  Another limitation is the 
lack of power for the study especially to detect associations with homozygous carriers of A-.  
In the present study, we propose to overcome some of these limitations through a 
longitudinal study with assessment of enzyme activity in the context of an ongoing study on 
malaria and pregnancy. 
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CHAPTER THREE - RESEARCH DESIGN AND METHODS 
 
 
Study design 
 
There are two main questions upon which this study is focused.  The first question 
concerns the effect of malaria and HIV infection on maternal anemia and birth weight.  This 
question will be investigated using data from a cohort study conducted among pregnant 
women followed from the second trimester to delivery.  The second question concerns the 
effect of G6PD deficiency on malaria, anemia and birth weight.  This question will be 
explored through a case-cohort study in which the sample is drawn from the same cohort of 
pregnant women employed in the first question. 
 
Study population  
 
The study population consisted of 1,496 pregnant women at <24 weeks of gestation 
attending the Mpemba and Madziabango Health Centres in Blantyre District, Malawi for 
antenatal care and delivery between March 2005 and February 2006.  The average age of the 
women was 23.7 (standard deviation (sd) = 5.45) and about a quarter of the women were 
primigravid (see Table 1).  The average gestational age at enrollment was 23 weeks (sd=3.6) 
and ranged between 14 and 28 weeks.  Almost a third (31.8%) of the women had parasitemia 
at enrollment and 94% agreed to voluntary testing and counseling (VCT). 
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Data collection 
 
Study nurses collected information on basic demographic characteristics, socio-
economic data and malaria prevention activities from the women attending the Health 
Centers (see appendix for questionnaires).  Women agreeing to VCT were HIV-tested on 
site, in addition to receiving pre- and post-test counseling.  At each visit, a finger-prick blood 
sample was collected for each woman for thick blood film examination for malaria parasites 
and determination of hemoglobin level.  For women delivering at the Health Centres, 
placental, cord and peripheral blood films were collected and examined for malaria parasites 
on site.  Birth weight was also recorded. For women not delivering at the Health Centers, an 
attempt was made to identify the women and record birth weight within 24 hours of delivery.  
Dried blood spot samples were also prepared at enrollment and delivery.  These samples 
were genotyped to determine carriage of the A- allele that confers G6PD deficiency in this 
population. 
 
Measurements 
 
Parasitemia 
Malaria was assessed through microscopic examination of thick blood smear slides 
on site by trained laboratory technicians after collecting finger prick blood samples from the 
participating women.  Malaria parasites were quantified against 200 white blood cells 
(WBC).  For quality control purposes, a 10% random sample of slides were re-examined by 
the laboratory supervisor at Ntcheu District Hospital.   
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HIV 
Among women agreeing to VCT, HIV infection was assessed using two rapid HIV-1 
antibody tests: Determine and Unigold.  There was 95% (95% confidence interval:  93.2 – 
97.8%) agreement between the two tests in identifying HIV positive women. 
 
G6PD deficiency 
A 30% simple random sample was drawn from the cohort of women followed until 
delivery who had filter paper blood spots available. Additionally, all women with malaria at 
delivery for whom filter paper blood spots were collected were also identified.  Carriage of 
the A- allele was assessed through genotyping of the blood spots according to a previously 
published method [1]. 
 
Maternal anemia 
Hemoglobin levels were estimated from the finger prick blood samples using 
HemoCue on site at each visit. 
 
Birth weight 
For women delivering at the Health Centres, birth weight was assessed after birth 
using simple spring balances. Through Community Nurses and Traditional Birth Attendants, 
an attempt was made to identify women not delivering at the Health Centres in order to 
obtain the birth weight within 24 hours of delivery. 
 
  22
 
 
Table 1. Characteristics of the study population
All Yes No
Variable (N=1,496) (N=476) (N=1020)
Maternal age (years), mean ± SD 23.7 ± 5.5 21.5 ± 4.8 24.7 ± 5.4
Education ≤ 8 years (%) 86.3 88.2 85.4
Married (%) 91.9 90.1 92.7
Unemployed (%) 52.7 56.3 51.1
Reported fever in previous week (%) 11.9 12.6 11.6
Previous antimalarials in this pregnancy (%) 9.6 6.7 10.9
Report always using bednet (%) 21.5 15.1 24.5
Report insecticide impregnation of bednet in past 6   to 
be months (%) 19.9 13.9 22.7
Gravidity (%)
     Primigravid 24.7 45.4 15.5
     Secundagravid 23.2 24.4 38.1
     Multigravid (≥3 pregnancies) 52.1 30.2 46.4
Gestational age (weeks), mean ± SD 23.3 ± 3.6 22.8 ± 3.5 23.5 ± 3.6
Weight (kg), mean ± SD 54.7 ± 6.8 53.9 ± 6.4 55.1 ± 6.9
HIV seropositive (%) 14.1 16.9 12.8
Hemoglobin (g/dL), mean ± SD 11.0 ± 1.6 10.5 ± 1.6 11.25 ± 1.6
Hemoglobin ≤ 10g/dL (%) 23.22 34.5 17.7
Hemoglobin ≤ 7g/dL (%) 1.82 1.9 1.8
Parasitemia
 
 
Data analysis 
 
Specific Aim 1.  What is the effect of malaria and HIV infection during pregnancy on 
maternal anemia and birth weight? 
 
Exposure definitions 
It is of interest to determine how malaria affects pregnancy outcomes while 
accounting for HIV infection, gravidity and other confounders (see Figure 1 for conceptual 
model).  Malaria is defined in various ways, and each way has implications for the type of 
analysis required.  Pregnancy outcomes may be affected by parasitemia at delivery, 
parasitemia throughout the pregnancy, number of episodes of parasitemia throughout the 
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pregnancy, parasite density at delivery, and parasite density of malaria episodes throughout 
the pregnancy.  Parasitemia can be conceived of as a dichotomous variable where the subject 
either has or does not have parasitemia.  Parasite density is a semi-continuous variable 
calculated from the number of parasites observed through microscopic examination of thick 
blood smears (see Table 2 for variable specifications). 
 
Outcome definitions 
In a manner similar to malaria, low birth weight and maternal anemia may also be 
dichotomized or treated as continuous variables (see Table 2 for variable specification). 
 
Analysis plan 
Objective 1. To determine the separate effects of HIV infection and malaria on maternal 
anemia and low birth weight 
 
 Binomial regression will be employed to estimate the relative risks for the separate 
(main) effects of  HIV infection and parasitemia and parasite density at delivery on 
dichotomized low birth weight and moderate/severe anemia at delivery, adjusting for 
important covariates (see Figure 1 and Table 2).  The effect of HIV infection and parasitemia 
and parasite density at delivery on continuous birth weight and hemoglobin levels at delivery 
will be assessed through linear models, adjusting for important covariates. 
 
Objective 2. To assess interaction between the effects of HIV infection and malaria on 
maternal anemia and low birth weight. 
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 Interaction on a multiplicative scale will be assessed by introducing an interaction 
term between HIV and parasitemia/parasite density in the above models. Additive interaction 
(for dichotomous outcomes) will be assessed through computation of relative excess risk due 
to interaction (RERI) [2]. 
 
Specific Aim 2. What is the effect of HIV infection on parasitemia risk at enrollment, during 
follow-up and at delivery? 
 
Objective 1. To describe the pattern of parasitemia risk over the second and third trimester. 
 
 At each visit, the proportion of women with parasitemia according to gravidity and 
HIV status will be computed  and presented in a graph.  Graphical analysis will be employed 
to describe the pattern of parasitemia over the follow-up visits. 
 
Objective 2. To estimate the effect of HIV on the risk of parasitemia and anemia at 
enrollment, over the follow-up period and at delivery. 
 
 Binomial regression will be employed to determine the effect of HIV infection on 
parasitemia at enrollment, anytime over the follow-up period and at delivery. Generalized 
estimating equations (GEE) will be used to determine the effect of HIV infection on 
parasitemia throughout the pregnancy, adjusting for demographic and socioeconomic 
variables, including education. GEE models are appropriate for clustered outcomes; however, 
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they are not robust to data not missing completely at random (MCAR). Hence, GEE models 
will be weighted with inverse-probability-of-missingness weights, using information 
obtained from the demographic and socioeconomic questionnaire to build the missingness 
models[3]. 
 
Objective 3. To determine the relationship between HIV infection and frequency and 
severity of parasitemia at delivery. 
 
 Polytomous logistic regression will be used to determine the effect of HIV 
infection on the frequency of parasitemia episodes. Since frequency is necessarily ordinal, 
proportional odds logistic regression will be most appropriate. However, if the proportional 
odds assumption is not met, generalized logistic regression with robust standard errors will 
be employed.  The effect of HIV infection on parasite density will be assessed using zero-
inflated negative binomial regression to account for excess zeros, since most women will not 
have parasitemia, and also to account overdispersion of parasite density. 
 
Specific Aim 3.  What is the relationship between carriage of the G6PD A- allele and 
parasitemia and anemia among pregnant women? 
 
Exposure definition 
Since the study population is a cohort of women and the gene for G6PD is on the X-
chromosome, G6PD deficiency can be defined as a categorical variable with three values, 
homozygous carriage, heterozygous carriage, and non-carriage of the mutant A- allele. 
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Outcome definitions 
Outcome definitions same as for specific aim 1. 
 
Analysis Plan 
A case- cohort design was employed to address the second specific aim. To estimate 
the effect of G6PD deficiency on birth weight and maternal anemia, analyses similar to those 
used for the first specific aim will be conducted among the 30% sub-cohort.  In order to 
determine the effect of G6PD deficiency on parasitemia/parasite density, binomial regression 
will be employed modeling the probability of carriage of the A- allele among cases versus 
carriage among the subcohort.  Binomial regression is appropriate especially for parasitemia 
since it is a common outcome in this population [4]. GEE will be used to determine the effect 
of G6PD deficiency on parasitemia and maternal anemia over follow-up, GEE will be used. 
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Figure 1. Causal model for specific aim 1. 
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Figure 2. Causal model for specific aim 2. 
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Figure 3. Causal model for specific aim 3. 
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Table 2. Variable specification 
Type Description
Parasitemia at delivery Binary 0 = No parasites detected, 1 = parasites detected
Parasitemia at visit Binary 0 = No parasites detected, 1 = parasites detected
Parasite density at delivery Continuous Parasite count per microliter, assuming 6000 WBC/µL
Parasite density at visit Continuous Parasite count per microliter, assuming 6000 WBC/µL
Visit Categorical 1=first visit, 2=second visit, etc
G6PD deficiency Categorical 0 = normal, 1 = heterozygous, 2 = homozygous
Birth weight Continuous Measured in grams (g)
Low birth weight Binary 0 = birth weight ≥ 2500g, 1 = birth weight < 2500g
Hemoglobin at delivery Continuous Measured in grams per deciliter (g/dL)
Hemoglobin at visit Continuous Measured in grams per deciliter (g/dL)
Anemia at delivery Binary 0 = Hb ≥ 10g/dL, 1 = Hb < 10g/dL
Anemia at visit Binary 1 = Hb ≥ 10g/dL, 1 = Hb < 10g/dL
Severe anemia at delivery Binary 0 = Hb ≥ 7g/dL, 1 = Hb < 7g/dL
Severe anemia at visit Binary 1 = Hb ≥ 7g/dL, 1 = Hb < 7g/dL
HIV Binary Determined by either Determine or Unigold Test
Gravidity Continuous Number of pregnancies carried
Primigravid Binary 0 = second or later pregnancy, 1 = first pregnancy
Gravidity Category Ordinal 1 = Primigravid, 2 = Secundagravid, 3 = >2 pregnancies
Education Ordinal 1 = none, 2 = primary, 3 = secondary or higher
Marital Status Binary 0 = Currently married, 1= Currently not married
Mother's occupation Categorical 1 = none, 2 = vendor, 3 = works for a wage
Husband's occupation Categorical 1 = none, 2 = vendor, 3 = works for a wage
Maternal weight Continuous Measured in kilograms (kg)
IPT received Ordinal 1 = one dose, 2 = 2 doses, 3 = 3 or more doses
Variable
Exposures
Outcomes
Covariates
 
 
 
Strengths and limitations of methods 
 
The aim of the proposed study is to estimate the effects of malaria, HIV and G6PD 
deficiency on pregnancy outcomes in a cohort of pregnant women in southern Malawi.  This 
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is an important and timely question, particularly in the development of new anti-malarial 
drugs.  The population of women sampled is appropriate for this study given the underlying 
prevalence of HIV, G6PD deficiency and malaria.  Furthermore, since Malawi has over 95% 
ANC coverage, by sampling from women attending ANC clinics, the cohort approximates a 
population-based sample [5].  This enhances the generalizability of the obtained results.  
Furthermore, collecting information on various socioeconomic variables lends strength to the 
study by providing a more complete picture of the context in which the disease occurs and 
allowing for a more thorough examination of factors that can confound or modify the effects 
of interest.  The longitudinal study design helps in assessing risk over the pregnancy.  This is 
especially important as many studies in the literature have been limited to effects at delivery 
or the third trimester. 
Despite these strengths, there are a number of limitations to be recognized.  One of 
the main limitations concerns the ability to minimize loss to follow-up.  In this population of 
women, delivery frequently occurs at the home, thus making it difficult to collect birth 
weight and other information at delivery.  This may reduce the generalizability of the study 
and introduce bias, particularly if women who are lost to follow-up are different from women 
who remain in the study until delivery.  To address this limitation, the probability of 
missingness for the outcome will be modeled in order to understand the factors contributing 
to loss-to-follow up and adjust analyses appropriately.   
 Another limitation, particularly for the third aim is that given the sample size, there 
will most likely be insufficient statistical power to detect effects among homozygous carriers.  
However, the number of homozygous carriers is usually small in most populations and would 
thus have a minimal impact on population attributable fraction of protection by G6PD 
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deficiency.  The study site and population also present some limitations.  The population is 
ethnically diverse, and by extension, is genetically heterogeneous.  This admixture may 
present unequal distributions of other genetic ‘responses’ to endemic malaria (e.g. HbS, α/β-
Thalassemia, etc.) that may be differential by outcome.  However, since these other 
characteristics have not been shown to be related to G6PD deficiency, they would not 
confound the results but may contribute to within- subjects error in the statistical models.  
A final consideration involves the study population and is a limitation inherent to 
most studies on pregnancy.  Since women usually have their first ANC clinic visit during the 
second trimester, women with very early pregnancy loss may be missed.  There is some 
indication that HIV, G6PD deficiency and malaria may independently contribute to 
pregnancy loss [6, 7].  Hence this may reduce generalizability since the women who do 
enroll are women who had sufficiently healthy pregnancies to reach the second and third 
trimester.   
Despite these limitations, the proposed study has a number of strong points and will 
add significantly to the literature on HIV, G6PD deficiency and malaria during pregnancy.  
One, the study will be conducted in a population of women living in a malaria endemic area 
among which there is a high frequency of both HIV infection and G6PD deficiency.  Two, 
because the study employs a prospective design, it will allow for the direct estimation of risk 
and will allow for the observation of temporality between the outcome and important 
confounding or modifying factors, an advantage not afforded by cross-sectional studies 
conducted at delivery.  Additionally the inclusion of socioeconomic variables will enhance 
understanding of the relationship between HIV, malaria and G6PD deficiency on pregnancy 
outcomes in terms in proximal and distal causal mechanisms. 
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CHAPTER FOUR - THE EFFECT OF HIV INFECTION AND PLASMODIUM 
FALCIPARUM PARASITEMIA ON PREGNANCY OUTCOMES 
 IN SOUTHERN MALAWI 
 
Abstract 
 
Background.  Plasmodium falciparum parasitemia and HIV are important independent risk 
factors for low birth weight and maternal anemia. The two infections may interact to increase 
risk of adverse pregnancy outcomes.  
Methods.  Between 2005 and 2006, we followed pregnant women enrolled between 14-28 
weeks gestation attending two antenatal care clinics in southern Malawi until delivery.  
Results.  Among 831 pregnant women followed until delivery, the prevalence proportions of 
HIV and placental parasitemia were both 13%.  HIV was associated with increased risk of 
LBW (adjusted prevalence ratio, PRadj=3.08, 95% confidence interval, CI, = 1.40, 6.79) and a 
138g reduction in birth weight.  Placental parasitemia was associated with an elevated risk of 
LBW (PRadj=1.79, 95% CI = 0.83, 3.84), as was having ≥3 episodes of peripheral parasitemia 
during follow-up (PRadj=2.68, 95% CI = 1.06, 6.79). Among multigravidae, dual infection 
resulted in 9.59 (95% CI: 2.51, 36.6) times the risk of LBW when compared to multigravidae 
with neither infection.  HIV infection was associated with increased risk of anemia (adjusted 
odds ratio, ORadj = 2.12, 95% CI: 1.09, 4.14), as was placental parasitemia (ORadj = 3.60, 
95% CI = 1.95, 6.64). There was no interaction in the effect of HIV and placental parasitemia 
on anemia risk. Conclusions.  HIV infection and parasitemia are important independent risk 
factors for adverse pregnancy outcomes. Among multigravidae, HIV infection and placental 
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parasitemia may interact to produce an impact greater than the sum of their independent 
effects.  These results underscore the need for malaria prevention strategies that appropriately 
target pregnant women across gravidities. 
 
Introduction 
 
Malaria is a tremendous public health challenge in Malawi, with almost 3 million 
reported cases, resulting in 7,000 deaths annually [1].  Each year in Malawi, there are 
approximately 500,000 pregnancies all at risk for malaria [2].  For these women, infection 
with Plasmodium falciparum parasites may result in adverse pregnancy outcomes including 
malaria-associated infant deaths [3, 4].  These adverse outcomes are mediated through 
placental malaria, a condition associated with intrauterine growth retardation, prematurity, 
and severe maternal anemia [5, 6]. These conditions can lead to low birth weight (LBW), one 
of the most important risk factors for neonatal mortality and developmental impairment [7, 
8]. 
HIV prevalence in Malawi is also high, with an estimated 12% of antenatal care clinic 
attendees affected [9].  HIV infection has also been found to be associated with adverse 
pregnancy outcomes, such as infant mortality and LBW [10, 11]. The increased risk of 
malaria coupled with HIV infection may interact to cause adverse pregnancy outcomes more 
pronounced than would be expected with HIV infection or malaria alone [12].  Studies 
conducted in Malawi, Tanzania, and Kenya have reported increased risk of neonatal 
mortality, maternal anemia and LBW in the presence of dual infection by malaria parasites 
and HIV, versus malaria parasitemia or HIV alone [13-15]. However, previous studies have 
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relied on a cross-sectional design, determining malaria parasitemia status at single points 
during pregnancy.  In this study, we evaluate the effects of HIV and malaria parasitemia 
during pregnancy on maternal anemia and LBW among a cohort of pregnant women in 
Malawi.   
 
Methods 
Study population and data collection procedures 
The study was conducted at the Mpemba and Madziabango Health Centres in a rural 
area of Blantyre District, Malawi. Between March 2005 and February 2006, healthy pregnant 
women in their second trimester attending the antenatal care clinics at the study sites were 
invited to participate .  At enrollment, study nurses collected information on basic 
demographic characteristics, socio-economic data and malaria prevention activities from 
participating women.  Women agreeing to voluntary counseling and testing (VCT) were 
tested for HIV on site, in addition to receiving pre- and post-test counseling.  HIV-infected 
women and their infants were given nevirapine according to national guidelines.  
Additionally, women found to be infected with HIV were referred to an antiretroviral 
treatment program.  Women attending the antenatal care clinics were administered 
sulfadoxine-pyrimethamine (SP) for intermittent presumptive therapy in pregnancy (IPTp) 
and treated for clinical malaria also according to national guidelines.  
Women attended visits according to the standard antenatal care guidelines with visits 
scheduled after enrollment occurring at approximately 26, 32 and 36-38 weeks of gestation.  
At each visit, a finger prick blood sample was collected for thick blood film examination for 
malaria parasites and determination of hemoglobin level.  For women delivering at the 
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Health Centres, placental, cord and peripheral blood films were collected and examined for 
malaria parasites on site.  Placental biopsies were not collected. Birth weight, measured with 
simple spring balances, was also recorded. For women not delivering at the Health Centers, 
an attempt was made to identify the women and record birth weight within 24 hours of 
delivery.   
 
Laboratory procedures 
Peripheral malaria parasitemia was assessed through microscopic examination of 
thick blood smear slides on site by trained laboratory technicians.  Malaria parasites were 
quantified against 200 white blood cells (WBCs).  Placental parasitemia was also assessed 
through thick blood smear.  For quality control, a 10% random sample of slides were re-
examined by the laboratory supervisor at Ntcheu District Hospital.  HIV infection was 
assessed using two rapid HIV-1 antibody tests: Determine® and UnigoldTM.  There was 95% 
(95% confidence interval:  93.2 – 97.8%) agreement between the two tests in identifying HIV 
positive women. CD4+ cell counts were not evaluated.  Hemoglobin levels were estimated 
from the finger prick blood samples using HemoCue on site at each visit and after partum. 
 
Definitions 
Parasitemia was defined as the presence of parasites in thick blood smears.  Parasite 
density per µL was computed assuming 6,000 WBC/µL of blood.  Among women with 
placental parasitemia, mild parasitemia was defined as <20,000 parasites/µL, and severe 
parasitemia as ≥ 20,000 parasites/µL.  Peripheral parasitemia over follow-up was defined as 
the number of episodes of parasitemia over the follow-up visits.   Since we could not 
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distinguish between recrudescence and reinfection, measurements of parasitemia were 
assumed to be independent across visits.  Malaria parasitemia at delivery was defined as 
peripheral and/or placental parasitemia upon delivery.  Fever was rarely observed, and was 
thus not included in the definition of parasitemia.  Anemia at delivery was defined as 
hemoglobin < 11g/dL.  HIV infection was defined as a positive result on two rapid tests: 
Determine® and UnigoldTM.  Discordant results were excluded from analyses.  Neonates were 
considered as having LBW if they weighed less than 2500g. For the sociodemographic 
characteristics, unsafe water sources were defined as unprotected wells, lakes, rivers or 
ponds. Low housing quality was defined as housing with grass roofs and mud or grass walls 
with open unscreened windows. 
 
Statistical analysis 
Bivariate and multivariate analyses for dichotomous outcomes were conducted using 
binomial regression. When the binomial regression model was unstable, logistic regression 
was used.  Continuous birth weight and hemoglobin were analyzed using general linear 
models.  
In order to assess confounding for dichotomous outcomes, bivariate analyses with potential 
confounding variables were performed for both the outcomes and the main exposures.  In the 
case of binary variables, if the resultant relative risks were less than or equal to 0.7 or greater 
than or equal to 1.3, they were considered as potential confounders.  The number of potential 
confounders included in final models was further narrowed using a change-in-estimate 
approach with a 10% cut-off.   Covariate inclusion for continuous outcomes models mirrored 
that of the binary outcomes models.  Interaction effects were assessed through the inclusion 
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of interaction terms in the models and using the spreadsheet by Andersson and colleagues to 
determine the relative excess prevalence due to interaction (REPI) [16].  All analyses were 
performed using SAS v9.1 (Cary, North Carolina). 
 
 
Ethical considerations 
Informed consent was obtained from all participating women in Chichewa. The study 
was reviewed and approved by the institutional review boards at the University of North 
Carolina at Chapel Hill and the University of Malawi College of Medicine. 
 
Results 
 
The study enrolled 1,496 women, of whom 831 completed follow-up until delivery 
with 590 delivering at the health centers.  Descriptive characteristics of the study population 
are reported in Table 1. On average, participating women attended three follow-up visits 
between enrollment and delivery.  The average age of the women was 23.4 years (standard 
deviation (SD) = 5.4).  The average gestational age at enrollment was 23 weeks (SD=3.6) 
and ranged between 14 and 28 weeks.  The prevalence of HIV was 13%. There were no 
significant differences in the main exposures and sociodemographic characteristics between 
women who were lost to follow-up and women who completed follow-up. There was, 
however, a difference in maternal weight, with women not lost to follow-up being on average 
0.81 kg heavier than women lost to follow-up.  There were no significant differences in the 
main variables  among women delivering at the health centers versus women delivering 
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elsewhere, except for peripheral parasitemia, with women delivering elsewhere slightly more 
likely to have peripheral parasitemia than women delivering at the health centers (PR = 1.11, 
95% CI: 1.06, 1.17).  
 
Low birth weight 
The incidence of LBW was 9%, and mean birth weight was 3055g (SD=478).  In 
bivariate analyses, HIV infection, placental parasite density ≥20,000/µL, and having ≥3 
episodes of peripheral parasitemia over follow-up were strongly associated with LBW (Table 
2).  Placental parasitemia was marginally associated with LBW in both bivariate and 
multivariate analyses. Further, only HIV infection and having ≥3 episodes of peripheral 
parasitemia over follow-up were strongly associated with LBW after adjusting for potential 
confounders (Table 2).  Additionally, the risk of LBW among primigravidae was nearly two 
times the risk among multigravidae, after adjusting for maternal weight, unsafe water source, 
gravidity and HIV status (Table 2). 
Multivariate analyses of mean birth weight revealed a 138g reduction in birth weight 
by HIV infection (Table 2).  Placental parasitemia at delivery did not result in a notable 
reduction in birth weight; however, the mean difference for experiencing peripheral 
parasitemia ≥3 times over follow up was large (-163, 95% CI: -351 to 26). Decreasing 
number of SP IPTp doses received was associated with decreasing birth weight (p <0.01, 
Table 2). Being primigravid was associated with a 208g decrease in mean birth weight (Table 
2).  
 
 
  41
 
 
Maternal anemia 
HIV infection and placental and peripheral parasitemia were associated with an 
increased risk of maternal anemia and reductions in mean hemoglobin, with placental 
parasitemia having the strongest effect (Table 3).  Maternal anemia risk varied with the 
degree of parasite density with a parasite density ≥20,000 parasites/µL resulting in the 
highest increased risk and the greatest reduction in mean hemoglobin. Maternal anemia risk 
was also associated with number of parasitemia episodes.  Women who experienced 2 or 
more parasitemia episodes had an increased anemia risk and significant reductions in mean 
hemoglobin.  Compared to women who received ≥3 doses of SP IPTp, receiving only 1 dose 
was associated with an elevated unadjusted risk of maternal anemia, but there were no 
significant differences in anemia risk according to doses of SP received after multivariate 
adjustment (Table 3). 
 
Interaction between effects of HIV and parasitemia on pregnancy outcomes 
No significant interaction effects between HIV and peripheral or placental 
parasitemia were found during multivariate analyses for both LBW and maternal anemia 
when all gravidities were analyzed together. The overall relative excess prevalence due to 
interaction (REPI) for LBW was 6.72 (95% CI: -3.65, 17.08).  The REPI indicates the 
amount of observed prevalence that is beyond the sum of the independent effects of HIV and 
placental parasitemia.  However, after stratifying by gravidity, the odds of LBW among 
multigravidae with both HIV infection and placental parasitemia were 9.6 (95% CI: 2.5, 
36.6) times as high as the odds among women with neither infection (Table 4).    
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Even after stratifying by gravidity, there was no evidence of interaction for the joint 
effects of HIV infection and placental parasitemia on maternal anemia risk (Table 4).  
However, the reduction in mean hemoglobin was significantly higher among dually infected 
multigravidae than in multigravidae with neither infection.  Among primigravidae, women 
with dual infection had the highest absolute reduction in hemoglobin levels, but the estimated 
difference was imprecise (Table 4). 
 
Discussion 
   
In this cohort of pregnant women HIV infection was associated with LBW and 
maternal anemia.  Both peripheral and placental parasitemia at delivery were associated with 
maternal anemia and LBW, with a stronger effect observed on maternal anemia. 
Additionally, having ≥3 episodes of parasitemia over follow-up was associated with 
increased LBW risk. Among multigravidae, there was some evidence of superadditive 
interaction between HIV infection and placental parasitemia at delivery in their joint effects 
on LBW. No interaction effects were observed for maternal anemia. 
 
Low birth weight 
HIV infection has previously been associated with an increased risk of LBW [10, 17].   
HIV-infected mothers in Kenya gave birth to infants weighing on average 99g less than 
infants born to HIV-uninfected mothers, but this reduction did not translate into a significant 
increase in the risk of LBW [13].  In this study, we found a 138g reduction in mean birth 
weight and a significant increase in the risk of LBW by HIV infection after adjusting for 
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gravidity and placental parasitemia.  Consistent with previous studies, placental parasitemia 
was found to be associated with elevated risk of LBW[18].  Peripheral parasitemia at 
delivery, however, was not significantly associated with LBW. 
A high parasite density (>20,000 parasites per µL) was associated with a substantial 
reduction in mean birth weight. These high parasitemias were rarely accompanied by fever. 
In Zimbabwe, the risk of LBW among pregnant women with symptomatic malaria was 10 
(95%CI: 6.50, 15.65) times that of women without malaria [17]. Taken together, these 
studies suggest that risk of LBW may be influenced by the severity of the malaria infection 
as indicated by degree of parasitemia and/or resulting morbidity. 
Our data suggest that the number of episodes of parasitemia is a key predictor of risk 
of LBW. Women who had ≥3 episodes of peripheral parasitemia over follow-up had a 
significantly increased risk (PR 2.68; CI 1.06-6.89) of LBW. We are only aware of one other 
published study which examines the relationship between frequency of parasitemia and birth 
outcomes. In the Democratic Republic of Congo, Landis and colleagues reported that women 
having ≥3 infections were at increased risk of intrauterine growth retardation [19]. Recently, 
in a similar population in Malawi, a significantly increased risk of LBW and maternal anemia 
was found in women experiencing ≥2 parasitemia episodes during follow up (Kalilani L, 
Mofolo I, Chaponda M, Rogerson SJ, Meshnick, SR; The effect of timing and frequency of 
Plasmodium falciparum infection during pregnancy; submitted).  This study also reports an 
attenuated increase in risk due to one episode; however, number of episodes includes 
parasitemia at delivery, whereas in the current study number of episodes excludes 
parasitemia at delivery.  These results suggest that parasitemia throughout the gestation 
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period, and not only at delivery should be considered when assessing the effect of malaria on 
LBW risk.   
Similar to previous studies, we did not detect any interaction between HIV infection 
and placental parasitemia in the effect on LBW overall [13, 20].   In the study conducted in 
Kenya, among HIV infected primigravidae, parasitemic women had 2.5 (95% CI: 1.0, 5.9) 
times the risk of LBW compared to aparasitemic HIV-infected women [13].  In contrast, in 
our study, in stratified analyses, among primigravid women, neither infection increased the 
risk of LBW in the presence of the other.  However, among multigravid women with 
placental parasitemia, HIV-infected women had almost 10 times the risk of LBW when 
compared to HIV-uninfected parasitemic women.  Although the confidence limit ratio of this 
estimate was 15 indicating imprecision, the magnitude of the estimate is strongly indicative 
of superadditive interaction. Furthermore, at the specified alpha-level of 0.10, the interaction 
term among multigravidae reaches statistical significance, further adding to the evidence of 
interaction.  
 
Maternal anemia 
HIV and peripheral and placental parasitemia were strong independent risk factors for 
maternal anemia at delivery and corroborating previous literature.  In the study by Van Eijk 
and colleagues, malaria and HIV were associated with a slightly elevated risk of anemia 
among all gravidities [21].  In the study conducted in Malawi by Rogerson and colleagues, 
both placental and peripheral parasitemia were associated with anemia (peripheral 
parasitemia OR=1.85, 95% CI: 1.45, 2.36; placental parasitemia OR = 2.0, 95% CI: 1.5, 2.7), 
where placental parasitemia was determined through histological examination [22].  In a 
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similar population, 2 or more episodes of parasitemia have been associated with a doubling 
of maternal anemia risk (Kalilani L, Mofolo I, Chaponda M, Rogerson SJ, Meshnick, SR; 
The effect of timing and frequency of Plasmodium falciparum infection during pregnancy; 
submitted). In the study conducted in Kenya by Ayisi and colleagues, however, among 
primigravidae, only HIV infection was independently associated with anemia (defined as Hb 
< 8g/dL).  We saw few women with such profound anemia. Among Kenyan multigravidae, 
no independent effects of HIV and parasitemia were detected; however, co-infection was 
strongly associated with increased risk of anemia [13].  These differences in results may be 
due to the differing definitions of maternal anemia. 
 
In contrast to the study in Kenya, we did not detect any interaction between HIV and 
peripheral or placental parasitemia in their effect on maternal anemia at delivery among both 
primigravidae and multigravidae [13].  Although the risk of anemia was highest among 
dually infected women, the estimate for the joint effect was not greater than the additive 
effects of HIV infection and placental parasitemia only. Furthermore, primigravidae 
exhibited a significant reduction in hemoglobin levels only among women with placental 
parasitemia in the absence of HIV infection.  Among multigravidae, we found no indication 
of interaction between HIV infection and placental parasitemia in their effect on mean 
hemoglobin levels. These differences in the influence of both HIV and malaria on maternal 
anemia risk may be due to differing distributions of HIV infection and gravidity differing 
definitions of anemia, and the multi-factorial nature of the etiology of anemia.   
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Limitations 
The interpretation of these results is subject to some limitations. One, placental 
parasitemia was determined through placental blood film instead of histological examination, 
a more sensitive method [22-24].  However, this would have resulted in misclassification that 
would have biased the estimates towards the null. Two, we did not have information on 
CD4+ counts or other clinical measures of the stage of HIV infection.  Given the association 
of HIV infection with age, this may have influenced the effects of HIV differentially 
according to gravidity.  Three, birth weight was available for approximately 70% of the 
women. While there were no significant differences in HIV status, malaria preventive 
behaviors and demographic variables between women delivering at the health centres and 
those delivering elsewhere, women delivering at the health centres were more likely to have 
peripheral parasitemia. This may limit the generalizability of the results to women delivering 
at the health centres versus women in the catchment area of the health centres. A fourth 
limitation concerns the multiple factors contributing to maternal anemia.  In this study, we 
did not assess nutritional status and the presence of other parasitic infections associated with 
anemia risk.  However, we were able to adjust for variables linked to anemia, such as 
socioeconomic factors and maternal weight. 
 
Conclusions 
This study confirms the deleterious effects of HIV infection and parasitemia during 
pregnancy.   We report an increase in LBW risk due to multiple parasitemia episodes. 
Further, we found evidence of interaction between HIV infection and placental parasitemia in 
increasing risk of LBW among multigravidae.  Contrasting previous results, we found no 
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evidence of interaction between HIV infection and placental parasitemia on maternal anemia 
risk.  These results underscore the need for continued research to understand the role of HIV 
in contributing to adverse pregnancy outcomes in malaria-endemic areas.    Furthermore, the 
differential effects according to gravidity highlight the importance of targeted malaria 
prevention programs to ensure that the benefits of protective measures, whether through IPTp 
or insecticide-treated nets, accrue to all pregnant women. 
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Tables  
 
Table 1. Characteristics of the study population 
 
N* % N % N %
Overall 831 100% 235 28.4 592 71.6
Age
     15 - 19 227 27.3 186 79.2 40 6.8
     20 - 24 286 34.4 43 18.3 241 40.7
     ≥ 25 318 38.3 6 2.5 311 52.5
Education ≤8 years 686 82.7 174 74.0 508 86.0
Married 757 91.3 184 78.6 569 96.3
Unemployed 433 52.1 144 61.3 287 48.5
Unsafe water source 197 23.7 48 20.4 148 25.0
Low housing quality 199 24.0 59 25.2 138 23.4
Report always using bednet 203 24.4 40 17.0 163 27.5
Report insecticide impregnation of bednet in past 6 
months 182 21.9 32 13.7 150 25.3
Weight (kg), mean ± SD 828 55.1 ± 6.9 235 54.4 ± 5.8 589 55.4 ± 7.3
HIV seropositive 102 13.5 14 6.5 88 16.5
Placental parasitemia 111 13.4 50 21.3 60 10.1
Peripheral parasitemia 112 13.5 49 20.9 62 10.5
No. times parasitemic over pregnancy
     0 444 53.4 69 29.4 372 62.8
     1 237 28.5 77 32.8 159 26.9
     2 84 10.1 46 19.6 38 6.4
     ≥3 66 7.9 43 18.3 23 3.9
SP doses received
     0 34 4.1 8 3.4 26 4.4
     1 156 18.8 35 14.9 121 20.4
     2 329 39.6 89 37.9 239 40.4
     ≥3 312 37.6 103 43.8 206 34.8
Hemoglobin (g/dL), mean ± SD 732 12.3 ± 1.7 196 12.3 ± 1.8 532 12.3 ± 1.7
Hemoglobin <11g/dL 65 8.9 17 8.7 48 9.0
Low birth weight (<2500g) 49 8.7 20 12.7 28 7.0
Birth weight (grams), mean ± SD 585 3055 ± 478 168 2902 ± 447 415 3118 ± 476
SD = standard deviation, g/dL= grams per deciliter, kg=kilograms
*Sums may not add up to 831 because of missing values
All women        Primigravida Multigravida
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Table 2.   Predictors of risk of low birth weight and mean birth weight 
 
Variable
HIV† 12 (26.7) 54 (11.5) 2.32 (1.34 - 4.00) 3.08 (1.40 - 6.79) -138 (-250 to -26)
Placental parasitemia at delivery 12 (24.5) 75 (14.7) 1.67 (0.98 - 2.85) 1.79 (0.83 - 3.84) -36 (-137 to 66)
Peripheral parasitemia at delivery 12 (24.5) 77 (15.0) 1.63 (0.96 - 2.77) 0.58 (0.27 - 1.25) -59 (-42 to 159)
No. of times parasitemic over 
follow-up
     0 23 (46.9) 276 (53.4) Reference Reference Reference
     1 13 (26.5) 151 (29.2) 1.03 (0.51 - 2.10) 0.90 (0.41 - 1.98) 6 (-110 to 122)
     2 2 (4.1) 53 (10.3) 0.45 (0.10 - 1.98) 0.34 (0.07 - 1.59) 35 (-136 to 205)
     3+ 11 (22.5) 37 (7.2) 3.57 (1.61 - 7.91) 2.68 (1.06 - 6.79) -163 (-351 to 26)
Parasite density at delivery 
(parasites/μL)
     0 37 (75.5) 437 (85.4) Reference Reference Reference
     1 - 20,000 9 (18.4) 69 (13.5) 1.54 (0.71 - 3.33) 1.53 (0.66 - 3.56) -53 (-183 to 78)
     
≥
 20,000 3 (6.1) 6 (1.2) 5.91 (1.42 - 24.6) 3.51 (0.76 - 6.28) -220 (-727 to 287)
SP doses received
     0 4 (8.2) 21 (4.1) 2.60 (0.78 - 8.62) 2.00 (0.55 - 7.22) -242 (-498 to 14)
     1 10 (20.4) 93 (18.0) 1.47 (0.63 - 3.43) 0.95 (0.36 - 2.54) -135 (-281 to 10)
     2 21 (42.9) 212 (41.0) 1.35 (0.67 - 2.73) 1.27 (0.60 - 2.67) -46 (-162 to 70)
     3+ 14 (28.6) 191 (36.9) Reference Reference Reference
Primigravid 20 (41.7) 140 (27.1) 1.54 (1.07 - 2.21) 1.98 (1.01 - 3.88) -208 (-290 to -126)
† n= 45 and 496, respectively
Adjusted mean birth 
weight (g) difference**              
(95% CI)
Crude prevalence ratio       
(95% CI)
Adjusted prevalence ratio*       
(95% CI)                             
*All parasitemia outcomes and SP doses entered in separate models. All models adjusted for maternal weight, water source, gravidity and HIV status. 
**All models adjusted for maternal weight, housing quality, gravidity and HIV status. 
CI = confidence interval, g = grams. 
<2500g 
(N=49)                          
n (%)
 ≥ 2500g 
(N=517)          
n (%)
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Table 3. Predictors of risk of maternal anemia and mean hemoglobin 
 
Hb < 11g/dl Hb ≥ 11g/dl
Variable
(N=65)           
n (%)
(N=667)             
n (%)
Crude prevalence ratio           
(95%CI)
Adjusted prevalence ratio                                            
(95% CI)
HIV† 17 (27.4) 70 (11.6) 2.36 (1.49 - 3.74) 2.12 (1.09 - 4.14) -0.74 (-1.13 to -0.36)
Placental parasitemia at delivery 21 (32.3) 84 (12.6) 2.57 (1.71 - 3.85) 3.60 (1.95 - 6.64) -1.07 (-1.44 to -0.70)
Peripheral parasitemia at delivery* 19 (29.2) 90 (13.5) 2.17 (1.42 - 3.31) 2.84 (1.53 - 5.28) -1.08 (-1.45 to -0.72)
Parasites density at delivery 
(parasites/μL)
     0 44 (67.7) 583 (87.4) Reference Reference Reference
     0 - 20,000 17 (26.2) 75 (11.2) 3.00 (1.63 - 5.52) 3.30 (1.73 - 6.28) -1.04 (-1.43 to -0.65)
     ≥ 20,000 4 (6.2) 9 (1.4) 5.89 (1.74 - 19.9) 5.97 (1.58 - 22.52) -1.26 (-2.21 to -0.32)
No. of times parasitemic over 
follow-up*
     0 30 (46.2) 366 (54.9) Reference Reference Reference
     1 16 (24.6) 187 (28.0) 1.04 (0.56 - 1.90) 1.07 (0.54 - 2.13) -0.30 (-0.72 to 0.11)
     2 10 (15.4) 66 (9.9) 1.85 (0.86 - 3.96) 2.27 (1.00 - 5.16) -0.74 (-1.34 to -0.12)
     3+ 9 (13.9) 48 (7.2) 2.29 (1.02 - 5.11) 2.34 (0.96 - 5.72) -0.96 (-1.66 to -0.26)
SP doses received*
     0 4 (6.2) 29 (4.4) 1.74 (0.56 - 5.45) 1.44 (0.45 - 4.63) -0.04 (-0.89 to 0.81)
     1 19 (29.2) 118 (17.7) 2.03 (1.04 - 3.95) 1.50 (0.73 - 3.07) -0.40 (-0.91 to 0.10)
     2 22 (33.9) 268 (40.2) 1.03 (0.55 - 1.94) 0.99 (0.52 - 1.90) -0.12 (-0.52, 0.29)
     3+ 20 (30.8) 252 (37.8) Reference Reference Reference
Primigravid 17 (26.2) 179 (27.0) 0.97 (0.63 - 1.49) 0.88 (0.47 - 1.67) 0.04 (-0.25 to 0.34)
† n = 62 and 602, respectively
Adjusted mean hemoglobin 
(g/dl) difference (95% CI)
**All models adjusted for maternal weight, water source, gravidity and HIV status. 
CI = confidence interval, g/dl = grams per deciliter, Hb=hemoglobin 
*All parasitemia outcomes and SP doses entered in separate models. All models adjusted for maternal weight, water source, gravidity and HIV status. 
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Table 4. HIV and placental parasitemia interaction effects 
 
Factor Primigravida Multigravida Primigravida Multigravida
Neither infection Reference Reference Reference Reference
HIV only 2.52 (0.44 - 14.47) 2.02 (0.62 - 6.57) -220 (-614 to 174) -99  (-305 to 106)
Parasitemia only* 1.65 (0.51 - 5.35) 0.59 (0.08 - 4.66) -162 (-377 to 53) 127 (-95 to 349)
Dual infection 6.37 (0.46 - 88.5) 9.59 (2.51 - 36.6) -174 (-843 to 495) -216 (-559 to 126)
Interaction p-value 0.8 0.1 0.4 0.2
Neither infection Reference Reference Reference Reference
HIV only 5.42 (1.79 - 16.40) 3.73 (1.47 - 9.47) -0.14 (-1.80 to 1.52) -0.89 (-1.51 to -0.28)
Parasitemia only 2.56 (0.27 - 24.01) 2.87 (1.25 - 6.60) -1.02 (-1.86 to -0.17) -1.16 (-1.92 to -0.40)
Dual infection 9.03 (0.68 - 120.09) 5.21 (1.53 - 17.7) -1.72 (-4.16 to 0.72) -1.68 (-2.82 to -0.54)
Interaction p-value 0.8 0.4 0.6 0.5
CI = confidence interval, g/dl = grams per deciliter. 
*Placental parasitemia
**All models adjusted for maternal weight, water source, gravidity and HIV status. 
Adjusted prevalence ratio (95% CI)** Adjusted mean differences (95% CI)**
Low birth weight (<2500g) Birth weight (g)
Anemia (Hb<11g/dl) Hemoglobin (g/dl)
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
CHAPTER FIVE - CHARACTERIZING THE EFFECT OF HIV ON MATERNAL 
PLASMODIUM FALCIPARUM PARASITEMIA RISK, FREQUENCY 
 AND SEVERITY DURING PREGNANCY 
 
 
Abstract 
 
Objective. To examine the relationship between HIV infection and the risk, frequency and 
severity of malaria parasitemia among pregnant women.  
Methods.  Between 2005 and 2006, we followed pregnant women attending two antenatal 
care clinics in southern Malawi from the second trimester of gestation until delivery. 
Information was collected on HIV infection and socio-demographic and malaria preventive 
behaviors.  Malaria parasitemia was assessed at each follow-up visit.   
Results. A total of 1,370 pregnant women were included in the analyses.  The prevalence of 
HIV infection was 14% and 32% of the women were parasitemic at enrollment. The 
prevalence of parasitemia at enrollment among HIV-infected primigravidae was 0.85 (95% 
CI: 0.34, 2.12) times that of HIV-uninfected primigravidae. and the risk ratio was 1.0 (95% 
confidence interval (CI): 0.4, 2.8) over follow-up.  Among multigravidae, the prevalence of 
parasitemia among HIV-infected women was 2.3 (95% CI: 1.6, 3.3) times that of HIV-
uninfected women at enrollment, and the risk ratio was 2.2 (95% CI: 1.5, 3.2)during follow-
up. HIV infection was not associated with frequency of parasitemia among primigravidae 
(Odds ratio (OR) = 1.49, 95% CI: 0.64, 3.51 for ≥3 episodes) . However, HIV-infected 
multigravidae were 4.8 (95% CI: 2.1, 10.9) times as likely to have ≥3 episodes of parasitemia 
compared to HIV-uninfected multigravidae.  Among both primigravidae and multigravidae, 
  55 
 
 
 
placental parasite density among HIV-infected women was on average 3.6 (95% CI: 1.8, 7.2) 
times as high as among HIV-uninfected women. Conclusions.  HIV-infection resulted in a 
constant elevated risk of parasitemia over follow-up among multigravidae but not among 
primigravidae.  HIV infection was also associated with increasing number of parasitemia 
episodes among multigravidae, but not among primigravidae.  However, HIV infection was 
associated with higher peripheral and placental parasite densities across gravidities.  These 
results underscore the need to target both primigravidae and multigravidae in malaria 
prevention. 
 
Introduction 
 
Each year, more than 20 million women become pregnant in malaria endemic areas 
[1, 2].  For these women, exposure to and subsequent infection with Plasmodium falciparum 
parasites may result in adverse pregnancy outcomes leading to an estimated 75,000 – 
200,000 malaria-associated infant deaths per year [3].  These adverse outcomes are thought 
to be mediated through placental malaria, a condition associated with spontaneous abortion, 
stillbirth, intrauterine growth retardation, prematurity, and severe maternal anemia [4]. The 
latter three conditions can lead to delivery of an infant with low birth weight, one of the most 
important risk factors for neonatal mortality [5]. 
Placental malaria occurs when pregnant women are infected by particular variants of 
P. falciparum that have special affinity for receptors expressed on the surface of placental 
cells.  These variants do not infect non-pregnant hosts and differ from other variants in their 
ability to evade host immune response.  For this reason, primigravidae are generally at 
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highest risk of infection.  With successive pregnancies, women gradually develop immunity 
to these new parasite populations, and the risk of placental malaria decreases [6]. 
However, this gravidity-dependent immunity seems to be disrupted by HIV infection, 
with HIV-infected multigravidae being at increased risk of placental parasitemia [7][8-10].  
However, the relationship between HIV and parasitemia among primigravidae remains 
unclear.  The purpose of the current study is to evaluate the effect of HIV infection on 
malaria parasitemia during pregnancy in a cohort of pregnant women in Malawi followed 
from the second trimester until delivery.  In order to appropriately characterize this 
relationship, we examine parasitemia in different ways: as parasitemia risk over the follow-
up period, number of parasitemia episodes, and peripheral and placental parasite density at 
delivery. 
 
 Methods 
 
 
The study population comprised women in their second trimester of pregnancy 
attending the Mpemba and Madziabango Health Centres in Blantyre District, southern 
Malawi for antenatal care and delivery between March 2005 and February 2006.  These two 
health centres are located in rural areas outside of Blantyre, the largest city in Malawi.  
Women consenting to participate in the study were administered a questionnaire by the study 
nurses at enrollment to collect information on basic demographic characteristics, socio-
economic factors and malaria prevention behaviors.  Enrolled women who also consented to 
receiving voluntary testing and counseling (VCT) were counseled and tested for HIV using 
two rapid HIV-1 antibody tests: Determine (Inverness Medical Innovations, Inc., Waltham, 
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MA) and Unigold (Trinity Biotech, Bray, Ireland). HIV-infected women were given 
nevirapine according to national guidelines and referred to an antiretroviral treatment 
program.  
Participating women were encouraged to attend visits scheduled according to 
standard antenatal care guidelines.  At each visit, a finger prick blood sample was collected 
for thick smear examination for malaria parasites and determination of hemoglobin level.  
Peripheral malaria parasitemia was assessed through microscopic examination of thick blood 
smear slides on site by trained laboratory technicians. Malaria parasites were quantified 
against 200 white blood cells (WBCs). Women were administered sulfadoxine-
pyrimethamine (SP) for intermittent presumptive therapy in pregnancy (IPTp) and treated for 
clinical malaria according to national guidelines. At delivery, placental, cord and peripheral 
blood samples were collected and examined for malaria parasites through thick smear.  For 
quality control purposes, a 10% random sample of slides were re-examined by the laboratory 
supervisor at Ntcheu District Hospital. Placental histology was not performed. 
 
Exposure 
HIV infection was defined as a positive result on the two rapid tests employed.  There 
was 95% (95% confidence interval (CI): 93.2 – 97.8%) agreement between the two tests in 
identifying HIV infected women.  Discordant results were excluded from analyses. 
 
Outcome 
Parasitemia was defined as the presence of parasites in thick blood smears.  Parasite 
density was computed assuming 6,000 WBC/µL of blood.  Frequency of peripheral 
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parasitemia over follow-up was defined according to the number of episodes of parasitemia 
over the follow-up visits.  Since we could not distinguish between recrudescence and re-
infection, measurements of parasitemia were assumed to be independent across visits.  Fever 
was rarely observed and was thus not included in the definition of parasitemia.  Parasitemia 
was analyzed in four ways: a) as parasitemia risk (any or none) at enrollment, delivery, and 
any time over the follow-up period, b) as a longitudinal outcome averaging parasitemia risk 
across follow-up visits, c) as the number of episodes of parasitemia over follow-up, d) as 
peripheral and placental parasite density at delivery. 
 
Statistical analysis 
Binomial regression was employed with the log link to estimate prevalence and risk 
ratios for parasitemia at enrollment, delivery and anytime during follow-up. Parasitemia risk 
over visits was analyzed using weighted generalized estimating equations (WGEE) in order 
to account for the possibility that data were missing at random (MAR). In these models, each 
individual response is weighted by the inverse probability of a missing response given the 
other responses, i.e., the probability of a missing measurement given the other measurements 
for a given subject [11]. We used the following model of covariates to estimate the weight: 
hik
k
khi XLogit ∑
=
+=
7
1
)( βαθ  
where 
θhi = Pr{missing response at visit h | non-missing response at visit h-1} 
In the above model, h indexes visits, i indexes subjects and h indexes covariates.  The set of 
covariates used in the dropout model included continuous maternal weight in kg, maternal 
age at enrollment, and indicators for access to an unsafe water source, less than 8 years of 
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education, primigravida, husbands’ occupation, and low housing quality. The polytomous 
outcome, number of parasitemia episodes, was analyzed using generalized logistic regression 
with robust standard errors.  Parasite density at delivery was analyzed using zero-inflated 
negative binomial regression.  
Covariate inclusion in regression modeling was decided using a causal diagram. 
Figure 1 presents a causal diagram of the relationship examined in the current study.  Malaria 
preventive behaviors are endogenous to socioeconomic/demographic factors and are thus 
coupled together.  In this data, age and gravidity were extremely correlated to the point of 
exchangeability.  Hence, the path going through gravidity was chosen for analysis, since this 
is the main confounder of interest.   
Interactions on ratio and difference scales were assessed through the inclusion of 
product terms in the models, and calculation of the relative excess risk or prevalence due to 
interaction (RERI or REPI) [12, 13].Weighted generalized estimating equations was 
conducted using the macro developed by Molenbergh & Verbeke (2005). All analyses except 
one were conducted using SAS v9.1 for Windows (SAS Inc., Cary, NC, USA).  Zero-
inflation negative binomial regression was conducted using StataSE v10 (StataCorp., College 
Station, Texas, USA). 
 
Ethical considerations 
Informed consent was obtained from all participating women in Chichewa. The study 
was reviewed and approved by the institutional review boards at the University of North 
Carolina at Chapel Hill and the College of Medicine at the University of Malawi. 
 
  60 
 
 
 
Results 
 
The overall study population comprised 1,496 pregnant women.  Among these 
women, 111 did not agree to receive VCT and 15 women had discordant HIV rapid test 
results, yielding 1,370 women for inclusion in the analyses, of whom 61% were followed 
until delivery.  The characteristics of women included in the study are presented in Table 1.  
Among primigravidae, there were stark differences between HIV-infected and HIV-
uninfected women in educational attainment and malaria prevention behaviors (Table 1, 
Figure 2).   A much higher proportion of HIV-infected primigravidae reported both using a 
bed net and treating the bed net with insecticide at regular intervals compared to HIV-
uninfected primigravidae. Furthermore, HIV-infected primigravidae had higher educational 
attainment and a much greater proportion reported having received the first dose of SP IPTp 
prior to enrollment in the study. A much higher proportion of HIV-infected primigravidae 
were also reported receiving antimalarials for treatment during pregnancy prior to 
enrollment.  Similar differences were not observed among multigravidae. 
Over the follow-up period, 41% of the women experienced at least one episode of 
parasitemia. Among these women, 35% experienced more than one episode over follow-up.  
Figure 2 presents the proportion of women parasitemic at each visit according to HIV 
infection status and gravidity.  Among primigravidae, at the enrollment visit, the proportion 
of women parasitemic was 18% lower among HIV-infected women, than HIV-uninfected 
women. However, for subsequent visits, higher proportions of parasitemia were generally 
observed among HIV-infected primigravidae.  Among multigravidae, however, the 
proportion of women parasitemic was similar to that observed among primigravidae for HIV-
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infected women, and consistently higher among HIV-infected women versus HIV-uninfected 
women across all visits. 
There was significant negative interaction between HIV infection and being 
primigravid at enrollment and anytime over follow-up, but not for parasitemia at delivery.  At 
enrollment, there was antagonistic interaction between HIV and being primigravid on a ratio 
scale (χ2=4.79, p = 0.03) and a difference scale (χ2=5.70, p = 0.02). The REPI was -0.851 
(95% CI: -1.351, -0.350). Similarly, for parasitemia anytime over the follow-up visit, there 
was antagonistc interaction on both the ratio scale (χ2=7.04, p = 0.01) and a difference scale 
(χ2=10.42, p = 0.001). The RERI was -1.032 (95% CI: -1.884, -0.179). However, there was 
no evidence of interaction at delivery on neither the ratio (χ2=0.67, p = 0.41) nor the 
difference scale (χ2=0.06, p = 0.81).  The REPI for placental parasitemia at delivery was 
0.039 (95% CI: -3.654, 3.731).  
The results of multivariate analyses are presented in Table 2.  After adjusting for 
various factors, HIV-infected primigravidae were slightly less likely to have parasitemia at 
enrollment; however, the result is imprecise with a confidence limit ratio (CLR) of 6.2.  The 
maximum likelihood estimate (MLE) for parasitemia anytime over the follow-up period 
indicates no difference between HIV-infected and HIV-uninfected women and has a CLR of 
7.4.  At delivery, however, the MLE indicates that the risk of placental parasitemia was 66% 
higher among HIV-infected primigravidae when compared with HIV-uninfected 
primigravidae, and the estimate is more precise (CLR = 3.9). Due to zero cell counts at some 
visits, the results from the wGEE analysis for primigravidae were unreliable and are thus not 
reported.  
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The risk ratio estimates for parasitemia over follow-up are much more consistent and 
precise for multigravidae.     The risk ratio estimates for parasitemia at enrollment, anytime 
during follow-up and at delivery are all indicative of an approximate doubling of risk due to 
HIV infection.  This is further confirmed by the results from the wGEE analysis. After 
adjusting for possible differential attrition (missingness at random), the estimate for the effect 
of HIV on parasitemia over the follow-up period is over 20% higher compared to the risk of 
having parasitemia anytime during follow-up (see Table 2).   
Low educational attainment among primigravidae was associated with parasitemia at 
enrollment (PR=2.25, 95% CI: 1.29, 3.91) and anytime over follow-up (RR= 1.80, 95% CI: 
1.01, 3.30). This was not the case among multigravidae, where  risk ratios were 1.76 (95% 
CI: 0.40, 2.15) and 1.10 (95% CI: 0.64, 1.90), respectively.  Reported use of a bednet was 
inversely associated with parasitemia at enrollment among primigravidae (PR=0.64, 95% CI: 
0.34, 1.21) and multigravidae (PR=0.67, 95%CI: 0.47, 0.97). For developing parasitemia 
anytime over follow-up, the effect estimate was greater among primigravidae (RR=0.47, 95% 
CI: 0.23, 0.94), than among multigravidae (RR=0.89, 95% CI: 0.61, 1.30). 
Among multigravidae, HIV infection was associated with increasing frequency of 
parasitemia episodes (Table 3).  A similar relationship was not observed among 
primigravidae. However, among primigravidae, low educational attainment was associated 
with increasing frequency of parasitemia episodes, and an inverse association with bed net 
usage was also observed. Receiving 2 doses of SP IPTp was also observed to be inversely 
associated with increasing frequency of parasitemia episodes, particularly among 
primigravidae. 
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Differences with respect to gravidity were not observed, however, for parasite density 
at delivery.  Across gravidities, HIV was associated with higher parasite density, with a 
greater effect estimate observed for placental parasite density (Table 4).  Independent of HIV 
infection, being primigravid was associated with nearly 300% higher placental parasite 
densities, but 100% higher peripheral parasite densities.  The predicted change in 
parasites/µL for placental parasitemia was similar for HIV infection and being primigravid.  
While both reporting regular use of bed net and treating the bed net with insecticide at 
regular intervals were associated with lower peripheral parasite densities, only reporting 
insecticide treatment of bed nets was associated with lower placental parasite densities.   
 
Discussion 
 
In the current study, we report the effect of HIV infection on malaria parasitemia in a 
cohort of pregnant women observed from the second trimester until delivery.  Whereas 
among multigravidae we observed a constant effect of HIV infection on parasitemia risk over 
the course of follow-up, primigravidae exhibited a gradual strengthening of the effect of HIV 
infection across visits.  Additionally, parasitemia risk across follow-up visits among HIV-
infected multigravidae was most similar to the risk among HIV-uninfected primigravidae.  
Further, HIV infection was observed to be associated with increasing frequency of 
parasitemia episodes among multigravidae, but not among primigravidae.  At delivery, 
however, the effect of HIV infection was associated with increased peripheral and placental 
parasite density across gravidities. 
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Parasitemia at enrollment 
One of the more unexpected results was the lower prevalence of parasitemia among 
HIV-infected primigravidae relative to HIV-uninfected primigravidae at enrollment.  In light 
of previous literature, we would have expected to see either a similar or a higher prevalence 
[7, 8, 10, 14].   The observed direction of this association, however, seems congruous with 
the stark differences in educational attainment and malaria preventive behaviors observed 
between HIV-infected and HIV-uninfected primigravidae.  For example, for most of the 
women, the enrollment visit was the first ANC visit and hence the first visit in which women 
would have received SP IPTp.  Yet, HIV-infected primigravidae were five times as likely to 
report already having received an SP IPTp dose before enrollment compared with HIV-
uninfected.  Furthermore, HIV-infected primigravidae were three times as likely to report 
using and treating bed nets with insecticide at regular intervals compared with HIV-
uninfected primigravidae.  These differences are consistent with the observed higher 
educational attainment among HIV-infected primigravidae, and the finding of a strong 
elevated risk of parasitemia at enrollment associated with low educational attainment. 
After adjusting for the factors, the value of the effect estimate was attenuated, but did 
not change direction, suggesting other potential factors.  Another possible explanation is that 
HIV-infected primigravidae may have been more likely to experience parasitemia earlier 
than the second trimester when they enrolled in the study.  HIV-infected primigravidae were 
more than 4 times as likely to report having received antimalarial treatment during the 
pregnancy prior to enrollment.  A similar relationship was not observed among 
primigravidae.  The finding of higher previous antimalarial use among HIV-infected women 
during pregnancy before initiation of SP ITPp has been observed in another study [7].  This 
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may indicate high parasitemia risk among HIV-infected women during early gestation.  In 
their study also conducted in southern Malawi, Verhoeff and colleagues report elevated 
prevalence of parasitemia in HIV-positive women at less than 16 weeks of gestation[7]. 
Recent malaria treatment prior to enrollment among HIV-infected women may also explain 
the lower prevalence of parasitemia at enrollment. 
 
Parasitemia risk over follow-up 
In this study we examine the risk of parasitemia over the follow-up period in two 
ways. The first way is experiencing parasitemia anytime over the follow-up period regardless 
of frequency; and secondly, as the average risk of experiencing parasitemia over the follow –
up visits accounting for frequency.  We report the results of the latter analysis only for 
multigravidae due to sparseness of data for primigravidae.  Among primigravidae, there was 
no evidence of elevated risk of parasitemia anytime over the follow-up period due to HIV 
infection.   In contrast, among multigravidae, HIV infection doubled the risk of parasitemia 
anytime over the follow-up period.  This effect was further strengthened when estimating the 
average risk of parasitemia over follow-up.  Nonetheless, there were no large differences 
among the effect estimates for HIV infection among multigravidae at enrollment, anytime 
during follow-up and averaged over follow-up visits, suggesting a constant effect over the 
follow-up period.  In contrast, the pattern of parasitemia risk observed across visits among 
primigravidae and the changing direction of effect estimates from enrollment until delivery 
suggested that the effect of HIV infection on parasitemia risk may vary over the course of 
pregnancy.  This may be due to the differential effects of SP IPTp between HIV-infected and 
HIV –uninfected women [15].   
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Frequency of parasitemia episodes 
The finding that HIV infection is associated with increasing number of parasitemia 
episodes corroborates previous literature.  In a study conducted in Malawian non-pregnant 
adults by Patnaik and colleagues, HIV infection increased the hazard of one episode 1.8 
times (95% CI: 1.2, 2.7), and two episodes 2.5 times (95% CI: 1.5, 4.2) [16].  In the present 
study, we report similar and more precise estimates for one and two episodes among 
multigravidae. Further, we found a very strong association between HIV infection and having 
three or more episodes of parasitemia among multigravidae. We did not observe a similar 
relationship among primigravidae.  Consistent with other findings in the current study, low 
educational attainment was a strong risk factor for two or more episodes of parasitemia 
among primigravidae.   
 
Parasitemia risk at delivery 
The elevated risk of placental parasitemia observed among primigravidae and 
multigravidae support finding from previous studies.  In a meta-analysis of the effect of HIV 
infection on malaria parasitemia, ter Kuile and colleagues summarizing data from four 
studies, three of which were conducted in Malawi,  reported a summary estimate of 1.27 
(95% CI: 1.06, 1.51) for the effect of HIV infection on placental parasitemia among 
primigravidae and 2.39  (95%  CI: 1.87, 3.07) among multigravidae[10].  The latter estimate 
is very similar in magnitude of effect to that reported in the current study, though the former 
differs most likely due to sparseness of data. This study confirms the hypothesis that the 
effect of HIV infection on placental parasitemia is more marked among multigravidae than 
among primigravidae. 
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Parasite density at delivery 
A difference in effect according to gravidity was not observed, however, for parasite 
density.  Across gravidities, HIV infection was associated with higher parasite density.  The 
result that HIV infection is associated with higher parasite density also corroborates previous 
research [8, 17, 18].  Interestingly, report of bed net use was associated with lower peripheral 
parasite densities, but not placental parasite densities. While, reporting treatment of bed nets 
with insecticide was associated with both lower peripheral and placental parasite densities.   
Departing from previous studies, we employed zero-inflated negative binomial 
regression (ZINB) to examine the effect of HIV infection and other factors on parasite 
density. The advantage of ZINB regression is that it takes into account the semi-continuous 
nature (excess zeros) of parasite density and allows for overdispersion in non-zero values of 
parasite density.  This is preferable to comparing geometric mean parasite density using 
student’s t-test and analysis of variance or performing analyses on log-transformed parasite 
density for two reasons. One, because of the high degree of skew in parasite density, log-
transformation may not result in a normal distribution of transformed values precluding use  
of tests with a normality assumption. Additionally, the optimal Box-Cox transformation that 
would result in a normal distribution may vary from population to population, given factors 
such as seasonality and transmission intensity that tend to differ across populations.  Two, 
back-transformation of transformed values may not result in sensible results. Whereas, ZINB 
regression appropriately takes into account the distribution of parasite density and allows for 
the estimation of a predicted mean change in parasite density which has utility in determining 
the impact of the risk/protective factors of interest on parasite burden. 
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Limitations 
There are a number of considerations in the interpretation of the results from this 
study. One of the main limitations is loss to follow-up. Almost 40% of women included in 
the analyses were lost to follow-up over the course of the study.  This may limit 
generalizability of the results, although no substantial differences were observed between the 
cohort at enrollment and women followed until delivery.  Additionally, in the longitudinal 
analysis, we accounted for loss to follow-up by weighing our analysis model by the inverse 
probability of being missing given a set of covariates that could potentially influence 
missingness.  Secondly, placental parasitemia was determined through thick smear instead of 
placenta histology, a more sensitive method. By the same token, because we were unable to 
distinguish if measurements of parasitemia at different visits were the result of recrudescence 
or re-infection, some women labeled as having multiple parasitemia episodes may have had 
chronic infection.  
An additional limitation is that we did not obtain information on CD4+ count which 
has been associated with parasitemia in previous studies (Laufer, 2006; Patnaik, 2005; 
Whitworth, 2000) [16-18]. The differences observed among primigravidae and multigravidae 
in the effect of HIV infection on parasitemia may be reflective of more advanced HIV 
disease in multigravidae. Further, since HIV infection may also be associated with early 
pregnancy loss, there may have been some selection bias in that HIV-infected women 
enrolled in the study were women with sufficiently healthy pregnancies to reach the second 
trimester.  This may be associated with a complex of other factors such as socioeconomic 
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status and may be differential according to gravidity, since primigravidae are generally at 
much higher risk of adverse pregnancy outcomes than multigravidae.   
These limitations, however, are counterbalanced by the strengths of this study.  
Firstly, the current study employed a longitudinal study design and analytical procedures 
enabling examination of parasitemia risk from the second trimester until delivery. Secondly, 
although there was substantial loss to follow-up, there were no significant differences 
between women at enrollment and women followed until delivery.  Furthermore, potential 
residual differences were accounted for in the analyses. By the same token, the richness of 
socio-demographic information recorded from the women that allowed for a comprehensive 
missingness model, also allowed for the examination of the role of other individual factors in 
determining parasitemia risk over the follow-up period. 
 
Conclusions 
With the reduced effectivenesss of SP IPTp among HIV-infected women, it is 
important that antenatal care services promote the full repertoire of malaria prevention 
methods. Our findings speak to the effectiveness of the use and regular treatment of bed nets 
with insecticide in reducing parasitemia risk and placental parasite density.    The study 
underscores the necessity of targeting both primigravidae and multigravidae for malaria 
prevention in areas with a high prevalence of HIV infection.  Further, although we report a 
constant elevated risk of parasitemia among multigravidae, our results suggest that the effect 
of HIV infection on parasitemia risk may vary over time among primigravidae.  Further 
studies are needed to understand the effect of HIV infection on parasitemia risk over the 
course of pregnancy. 
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Tables 
Table 1. Study population characteristics 
Variable
HIV-infected      
(N=23)
HIV-uninfected  
(N=316)
HIV-infected     
(N=162)
HIV-uninfected   
(N=865)
Maternal age(years), mean ± SD 19.2 ± 2.7 18.3 ± 1.9 26.5 ± 4.2 25.3 ± 5.3
Education ≤8 years (%) 43.5 80.7 89.4 89.9
Married (%) 65.2 81.6 94.4 96.1
Unemployed (%) 52.2 61.1 46.3 51.1
Report always using bednet (%) 34.8 13.0 24.1 25.9
Report insecticide impregnation of bednet in 
past 6 months (%) 30.4 11.5 22.8 22.3
Weight (kg), mean ± SD 56.9 ± 7.8 53.6 ± 5.7 54.7 ± 6.8 55.1 ± 6.9
Parasitemia at enrollment (%) 43.5 58.9 37.0 20.7
Placental parasitemia (%) 28.6 22.3 19.3 8.3
Peripheral parasitemia at delivery (%) 28.6 21.3 20.5 8.3
No. times parasitemic over pregnancy (%)
     0 47.8 27.9 50.0 67.7
     1 26.1 37.0 30.9 26.1
     2 4.4 20.9 8.6 5.6
     3+ 21.7 14.2 10.5 1.2
SP doses received (%)
     0 8.7 5.1 8.6 5.9
     1 26.1 19.6 32.7 26.9
     2 30.4 38.6 32.7 38.5
     3+ 34.8 36.7 25.9 28.7
Anemia at enrollment (Hb ≤ 10g/dL) (%) 31.8 43.1 35.8 15.0
Anemia at delivery (Hb ≤ 10g/dL) (%) 15.4 8.9 20.3 7.4
Birth weight (grams), mean ± SD 2767 ± 514 2931 ± 428 2968 ± 544 3140 ± 461
SD = standard deviation, g/dL= grams per deciliter, kg=kilograms
Primigravida Multigravida
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Table 2. Estimated effect of HIV on parasitemia risk at different time points and over follow-up. 
Time point HIV+ HIV- HIV+ HIV-
Enrollment 10/23 186/316 0.85 (0.34, 2.12) 60/162 179/865 2.28 (1.58, 3.28)
Anytime during follow-up* 8/20 243/291 1.04 (0.38, 2.81) 48/140 148/760 2.16 (1.45, 3.21)
Delivery 4/14 45/202 1.66 (0.72, 2.81) 17/88 37/447 2.44 (1.28, 4.66)
Average risk over follow-up*†
---- ---- ---- varies varies 2.63 (1.08, 6.44)
Prevalence Ratio 
(95% CI)
Primigravidae Multigravidae
Models adjusted for education, maternal weight, bednet use, and number of SP doses received.
Fraction Parasitemic (n/N) Fraction ParasitemicPrevalence Ratio 
(95% CI)
*Excludes enrollment visit, risk ratio
†Primigravidae wGEE results not reported due to sparseness of data across visits, average risk over follow-up, frequencies vary 
according to visit.
 
 
 
 
 
 
Table 3. Risk factors for number of parasitemia episodes over follow-up 
Variable
Primigravida       
(n=123)
Multigravida      
(n=276)
Primigravida      
(n=67)
Multigravida      
(n=62)
Primigravida     
(n=50)
Multigravida      
(n=27)
HIV infection 0.76 (0.38, 1.54) 1.31 (1.02, 1.67) 1.40 (0.68, 2.89) 2.20 (1.53, 3.15) 1.49 (0.64, 3.51) 4.82 (2.12, 10.96)
Less than 8 years of education 1.08 (0.78, 1.51) 1.06 (0.77, 1.46) 1.77 (0.99, 3.15) 0.86 (0.52, 1.43) 1.98 (0.90, 4.37) N/A
Report always using bednet 0.64 (0.42, 0.99) 0.96 (0.77, 1.19) 0.62 (0.32, 1.17) 0.96 (0.18, 5.00) 1.01 (0.55, 1.85) 0.95 (0.41, 2.20)
SP doses received
     0-1 1.44 (0.96, 2.17) 1.19 (0.93, 1.53) 1.03 (0.57, 1.84) 0.73 (0.45, 1.18) 0.54 (0.19, 1.55) N/A
     2 0.75 (0.55, 1.01) 0.97 (0.78, 1.20) 0.63 (0.42, 0.96) 0.68 (0.47, 1.00) 0.50 (0.29, 0.86) 0.48 (0.21, 1.10)
     3+ Reference Reference Reference Reference Reference Reference
PR = Prevalence Ratio, RR = Risk Ratio, CI = Confidence Interval, Primigravidae (N = 339), Multigravidae (N=1122)
*Excluding enrollment visit
One episode only                                     
PR (95%CI)*
Two episodes                                            
RR (95%CI)*
Three or more episodes                  RR 
(95%CI)*
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Table 4. Multivariate predictors of parasite density at delivery 
Variable
Ratio of  average 
densities (95%CI) Predicted change 
in parasites/μL (SD)
Ratio of  average 
densities (95%CI) Predicted change 
in parasites/μL (SD)
HIV infection 2.59 (1.25, 5.34) 646 (108) 3.56 (1.76, 7.21) 1,700 (253)
Primigravid 2.03 (1.11, 3.73) 419 (131) 3.97 (2.16, 7.30) 1,700 (410)
Maternal weight, kilograms (continous) 0.94 (0.89, 1.00) -420 (74)** 0.89 (0.85, 0.92) -2,300 (310)**
Report always using bednet* 0.42 (0.20, 0.87) -130 (67) 1.22 (0.57, 2.62) ----
Report insecticide impregnation in past 6 
months 0.35 (0.17, 0.73) -150 (79) 0.19 (0.04, 0.94) -440 (260)
CI = Confidence Interval, SD= Standard deviation, N=831
*All variables in model. Bednet model excludes insecticide impregnation variable.
**Predicted change for maximum difference in maternal weight
Peripheral Placental
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Figures 
 
Figure 1. Causal diagram of HIV and parasitemia relationship in pregnancy 
 
 
 
 
Figure 2. Parasitemia across visits among primigravidae and multigravidae (Note: Value for 
visit 2 carried over to visit 3 among HIV infected primigravidae due to sparseness of data). 
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Figure 3. Frequency of selected factors among primigravidae (A) and multigravidae (B) 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
CHAPTER SIX - THE EFFECT OF G6PD A- DEFICIENCY ON PLASMODIUM 
FALCIPARUM PARASITEMIA AND ANEMIA AMONG  
PREGNANT WOMEN IN SOUTHERN MALAWI. 
 
 
Abstract 
 
Objective. The objective of this study was to determine the effect of carriage of the G6PD 
A- allele on maternal parasitemia, maternal anemia and low birth weight. 
Methods. Between 2005 and 2006, we followed pregnant women attending two antenatal 
care clinics in southern Malawi from the second trimester of gestation until delivery. We 
conducted a case-cohort study by sampling all cases of placental parasitemia at delivery and 
a 35% random sample of all women followed until delivery comprised a sub-cohort.  The 
G6PD status of the subcohort and all cases was assessed. 
Results. There were 46 cases of placental parasitemia and 294 women were included in the 
subcohort.  The prevalence estimates of placental parasitemia and G6PD A- allele carriage in 
the subcohort were 16% and 28% respectively.  G6PD A- primigravidae were as likely to 
have placental parasitemia as G6PD-normal primigravidae (PR=1.0, 95% confidence interval 
(CI): 0.7, 1.3). Among multigravidae, G6PD A- carriers were 0.9 (95% CI: 0.8, 1.0) times as 
likely to have placental parasitemia as G6PD-normal women. Further, their placental parasite 
density was on average 0.22 times that of G6PD-normal multigravidae.  Among 
primigravidae, G6PD A- carriers had 1.7 (95% CI: 1.0, 2.9) times the average risk of 
maternal anemia over the follow-up period when compared to G6PD-normal women. A 
similar relationship was not observed for multigravidae.  Across gravidities, G6PD 
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deficiency was associated with an increased risk of low birth weight (PR=2.5, 95% CI: 1.2, 
5.2).  Among daughters, G6PD A- carriage by the mother was associated with a 286g 
reduction in mean birth weight (p = 0.02). A reduction in mean birth weight was not 
observed among sons. 
Conclusions. The results of this study suggest a lack of a protective effect for G6PD A- 
carriage on parasitemia and anemia risk.  However, among multigravidae, G6PD A- carriage 
may protect against high parasite density. We also found an increased risk of low birth 
weight due to maternal G6PD A- allele carriage. More studies will need to be conducted to 
understand the role of G6PD A- in adverse birth outcomes. 
 
Introduction 
 
 
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most prevalent enzyme 
deficiency with over 300 million people affected worldwide [1].   The enzyme catalyzes the 
first rate-determining step in the pentose phosphate pathway that forms part of glycolysis [2].  
In the erythrocyte, the conversion of glucose-6-phosphate into 6-phosphogluconolactone, 
catalyzed by G6PD is very important for the production of reduced nicotinamide adenine 
nucleotide phosphate (NADPH), a compound crucial to the erythrocyte’s ability to withstand 
oxidative stress [2]. 
The geographic distribution of G6PD deficiency and its spatial correlation with areas 
of historic and present endemic malaria have led to the hypothesis that the deficiency may 
confer protection against malaria.  Various observational and in vitro studies have been 
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conducted to test this hypothesis [3-7].  Few studies, however, have been conducted among 
pregnant women. 
In malaria-endemic areas, pregnant women, especially primigravidae, are generally at much 
increased risk of malaria infection than non-pregnant adults [8, 9].  This elevated risk is 
mediated through particular variants of P. falciparum that have special affinity for the 
chondroitin sulphate A (CSA) receptor expressed on the surface of placental cells leading to 
placental infection [10, 11].   Placental malaria has adverse consequences for the mother and 
the fetus, such as low birth weight, intrauterine growth retardation, prematurity, and severe 
maternal anemia [12, 13]. With increasing gravidity, there is increasing production of 
antibodies that help reduce adhesion of infected cells to the CSA receptor, leading to a lower 
risk of placental malaria among multigravidae [14].   
In this study we employ a case-cohort design to assess the effect of G6PD deficiency 
on malaria parasitemia and maternal anemia risk among pregnant women followed from the 
second trimester until delivery.  
 
Methods 
 
Study population.  This case-cohort study was drawn from a cohort of 1, 496 
pregnant women in their second trimester attending the Mpemba and Madziabango antenatal 
care clinics located in a rural area outside of Blantyre, the largest city in Malawi. Women 
were enrolled between March 2005 and February 2006 in a cohort study examining the effect 
of HIV infection and malaria parasitemia on pregnancy outcomes. Women attended visits 
according to the standard antenatal care guidelines with visits scheduled after enrollment 
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occurring at approximately 26, 32 and 36-38 weeks of gestation.  At each visit, a finger prick 
blood sample was collected for thick blood film examination for malaria parasites and 
determination of hemoglobin level.  For women delivering at the clinics, placental and 
peripheral blood films were collected and examined for malaria parasites on site.  Placental 
biopsies were not collected.  Women attending the antenatal care clinics were administered 
sulfadoxine-pyrimethamine (SP) for intermittent presumptive therapy in pregnancy (IPTp) 
and treated for clinical malaria also according to national guidelines.  The sub-cohort used 
for the analyses comprised a 35% simple random sample without replacement of the 831 
women who completed follow-up until delivery. 
Case definitions. Parasitemia was defined as the presence of parasites in thick blood 
smears.  Malaria parasites were quantified against 200 white blood cells (WBCs) by trained 
laboratory technicians.  For the purpose of the case-cohort analyses, a case was defined as a 
woman presenting with placental parasitemia at delivery.  For sub-cohort analyses, case 
definitions extended to peripheral parasitemia at delivery, enrollment, and the follow-up 
visits.  Fever was rarely observed and was thus not included in the case definitions.  Anemia 
was defined as hemoglobin ≤ 11g/dL. Low birth weight (LBW) was defined as a birth weight 
< 2500g. 
Exposure definition. G6PD deficiency was defined as heterozygous or homozygous 
carriage of the A- allele. The presence of the G6PD A- allele was determined as previously 
described [6]. G6PD normal status was defined as the absence of the G6PD A- allele. 
Additionally, hemoglobin types and the presence of the 3.7-kb deletional determinant of 
α(+)-thalassemia was determined as described[15]. 
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Statistical analysis. Binomial regression was employed to estimate the effect of 
carriage of the G6PD A- allele on parasitemia and anemia risk at delivery, enrollment, and 
any time over follow-up.  For analyses involving parasitemia-related outcomes, both the case 
series and the subcohort were employed using inverse of sampling fraction weights. 
Binomial regression was also used to determine the effect of G6PD A- carriage on low birth 
weight. Analysis of variance was used to examine differences in mean birth weight.  
Generalized estimating equations were employed to determine the effect of G6PD A- allele 
carriage on parasitemia and anemia risk averaged over follow-up visits.  Zero-inflated 
negative binomial regression was used to determine the effect of G6PD A- carriage on 
parasite density.  Since G6PD deficiency is inherited at birth and the antimalarials used for 
IPTp and treatment are not known to induce hemolysis in G6PD-deficient individuals, there 
were no confounders of its relationship with parasitemia or anemia risk.  However, gravidity 
was investigated as an effect modifier through inclusion of interaction terms and stratified 
analyses. 
Ethical considerations. Informed consent was obtained from all participating women 
in Chichewa. The study was reviewed and approved by the institutional review boards at the 
University of North Carolina at Chapel Hill and the College of Medicine at the University of 
Malawi. 
 
Results 
 
Characteristics of the study population are presented in Table 1.  There were no 
significant differences between the sub-cohort and the full cohort.  A normal G6PD genotype 
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was observed for 72% of the sub-cohort and 80% of the cases.  There were 5 homozygous 
carriers among the sub-cohort and none among the cases. The prevalence estimate for sickle 
cell trait was 6%.  The prevalence estimates for heterozygous (-α/αα) and homozygous (-α/-
α) α (+)-thalassemia trait were 45% and 10%, respectively. The relationship between there 
red blood cell polymorphisms and pregnancy outcomes will be explored in a subsequent 
paper. In comparison to the sub-cohort, there was a greater proportion of primigravidae 
among cases. 
 
Plasmodium falciparum parasitemia 
According to the case-cohort analysis, both primigravid and multigravid G6PD A- 
carriers had a lower prevalence of placental parasitemia compared with G6PD normal 
women (PR= 0.77, 95% CI: 0.17, 3.42; PR=1.15, 95% CI: 0.50, 2.69, respectively).  
However, with confidence limit ratios (CLRs) of 20 and 5, respectively, these estimates were 
highly imprecise.  In the weighted analyses, there was no evidence of a difference in 
prevalence of placental and peripheral parasitemia among G6PD A- carriers versus G6PD 
normal women (Table 2). 
We also examined the effect of G6PD A- carriage on peripheral parasitemia at 
delivery, enrollment and over follow-up using the subcohort.  A difference in prevalence was 
not observed among G6PD A- carriers and normal women at delivery and enrollment.  
Among primigravidae, G6PD A- carriers had a 28% higher prevalence of parasitemia when 
compared with G6PD normal primigravidae anytime over follow-up.  However, a similar 
relationship was not observed with parasitemia averaged over the follow-up visits.  The 
estimates among multigravidae were similar in magnitude, but exhibited higher variance 
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(Table 2).  For parasite density at enrollment, no significant effects were observed for both 
primigravidae and multigravidae. However, at delivery, multigravid G6PD A- carriers had on 
average much lower parasite densities than G6PD normal multigravidae (Table 3). 
 
Maternal anemia 
Maternal anemia prevalence was higher among cases than among the subcohort, but 
the difference was more pronounced at delivery than at enrollment (Table 1).  At delivery, 
the effect estimates for G6PD A- carriage were on the side of protection for both 
primigravidae and multigravidae. However, with CLRs of 67 and 11, the estimates were 
extremely imprecise to be reliable.  At enrollment, there was significant negative interaction 
between carriage of the G6PD A- allele and gravidity, with G6PD A- carriage being 
associated with two times the prevalence of parasitemia among primigravidae when 
compared with G6PD normal primigravidae. Among multigravidae, however, the effect 
estimate for anemia at enrollment was in the direction of protection.  This relationship 
persisted even after adjusting for parasitemia.  At enrollment, among primigravidae with 
parasitemia, G6PD A- carriage was associated with 1.31(95% CI: 0.66, 2.59) times the risk 
of anemia when compared to normal G6PD.  Among multigravidae with parasitemia, G6PD 
A- carriage was associated with 0.93 (95% CI: 0.22, 3.89) times the risk of anemia when 
compared with normal G6PD. Effects on opposite sides of the null for primigravidae and 
multigravidae were also observed when examining average anemia risk over the follow-up 
period although the interaction effect was not significant. There was no evidence of 
interaction between number of SP doses received for IPTp and G6PD A- carriage in their 
effect on anemia. 
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Birth weight 
With regard to birth outcomes, across gravidities, G6PD A- carriers’ offspring 
exhibited a higher prevalence of low birth weight compared to the offspring of G6PD normal 
women (Table 2).  However, this translated into a significant difference in mean birth weight 
only among primigravidae.  On average, G6PD A- primigravidae bore infants weighing 203g  
less than G6PD normal primigravidae (p = 0.05).  Whereas, there was a 76g difference 
between G6PD A- and normal multigravidae (p=0.36, Figure 1). Further, among G6PD A- 
carriers, sons had a higher mean birth weight than daughters (+346g, p = 0.03). A similar 
difference was not observed among G6PD normal women (+36g, p=0.6). Daughters of G6PD 
A- carriers had a higher prevalence of low birth weight and significantly lower mean birth 
weight than daughters of G6PD normal women (Figure 2, Table 5). However, sons of G6PD 
A- carriers had a mean birth weight similar to sons of G6PD normal women, but a higher 
prevalence of low birth weight (Figure 2, Table 5). These differences differed according to 
gravidity. Among primigravidae, there was a reduction in mean birth weight for both sons 
and daughters born to G6PD A- deficient women.  However, among multigravidae, sons born 
to G6PD A- deficient mothers had higher average birth weights (Table 5). There was no 
significant difference in the sex ratios according to G6PD status. The ratio of sons to 
daughters among G6PD A- carriers offspring was 1.2; and among G6PD-normal women, 
0.95.   Further, among G6PD normal women, the difference in proportions of daughters born 
to women with placental parasitemia versus sons was 4% (95% CI: -4%, 13%); for G6PD A- 
carriers, 0% (95% CI: -17%, 20%). 
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Discussion 
 
In this study, we report the absence of a protective effect by G6PD A- carriage on the 
risk of malaria parasitemia and maternal anemia over pregnancy. At delivery, we report the 
absence of a protective effect of G6PD A- carriage on peripheral parasitemia among both 
primigravidae and multigravidae. However, we found a minimal protective effect among 
G6PD A- multigravidae.  We also found a reduced peripheral and placental malaria parasite 
density among multigravid G6PD A- carriers.  Additionally, we report an increased risk of 
low birth weight for neonates born to G6PD A- carriers.  The difference in mean birth weight 
was found to be more pronounced for daughters than for sons. 
 
Plasmodium falciparum parasitemia 
To our knowledge this is the first study reporting the effect of G6PD A- carriage on 
malaria parasitemia at delivery.  Using a case-cohort design, the resultant prevalence ratios 
suggested protection by G6PD A- carriage. However, the confidence limits crossed the null 
and the CLR’s ranged between 4 and 5, indicating imprecise estimates.  In contrast, for the 
sub-cohort analyses, the CLRs were much lower and the estimates closer to the null. For 
primigravidae, the maximum likelihood estimate was close to 1.0 indicating the lack of a 
relationship.  
There is one other study that reports the effect of G6PD A- carriage among pregnant 
women. In the cross-sectional study conducted by Mockenhaupt and colleagues among 
pregnant women in Ghana, the authors report a prevalence odds ratio of 0.6 (95% CI: 0.4 – 
0.9) for the effect of heterozygous carriage of G6PD A- allele on parasitemia among 
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multigravidae [16].  However, given that parasitemia was a very common outcome in the 
population (over 60% of the women were infected with P. falciparum), the use of logistic 
regression would result in estimates strongly biased away from the null.  Binomial regression 
is more appropriate when outcomes are common [17, 18]. Using binomial regression on the 
data from the study by Mockenhaupt and colleagues, the appropriate estimate of the 
prevalence ratio was found to be 0.81 (95% CI: 0.52, 1.26). This is similarly indicative of a 
lack of an association between G6PD A- carriage and parasitemia among mostly 
heterozygous multigravid G6PD A- carriers. Similar to the study conducted in Ghana, we 
also did not find a protective effect of G6PD A- carriage earlier in gestation. 
Although we did not detect protection against parasitemia by G6PD A- allele 
carriage, in this study we found significantly lower parasite densities at delivery associated 
with G6PD A- carriage among multigravidae.  Multigravid G6PD A- carriers had on average 
78% lower placental and 65% lower peripheral parasite densities at delivery when compared 
to G6PD normal multigravidae.   This finding suggests a possible interaction between G6PD 
deficiency and gravidity-dependent immunity to P. falciparum infection whereby the 
inhibition of parasite growth and enhanced phagocytosis of infected cells mediated by G6PD 
deficiency coupled with gravidity-dependent production of antibodies  inhibiting adhesion of 
infected erythrocytes to CSA may result in an anti-parasitic effect stronger than would be 
expected by either factor acting alone [7, 11, 14, 19, 20]. In vitro studies are needed to 
understand the effect of G6PD deficiency on parasite adherence and infection of erythrocytes 
in the placental circulation. 
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Maternal anemia 
  In this study we report an increase in risk of maternal anemia at enrollment and 
averaging over the follow-up period associated with G6PD A- carriage among primigravidae.  
Because malaria parasitemia is most frequent early during the follow-up period and decreases 
as women approach delivery, due to the receipt of IPTp, the increased risk of parasitemia 
could be due to infection induced hemolysis among G6PD A- carriers.  This would be more 
pronounced among primigravidae, who generally have a higher risk of P. falciparum 
parasitemia than multigravidae living in holoendemic areas.  Among multigravidae, there is 
some evidence of a protective effect of G6PD A- carriage on anemia at enrollment and 
averaging over the follow-up period.  The prevalence ratio reported in the current study for 
anemia risk over follow-up is similar to the prevalence ratio obtained from data from the 
Mockenhaupt study for infected multigravidae (PR=0.71, 95% CI: 0.39, 1.28, authors report 
OR=0.50, 95% CI: 0.3, 1.0) [16]. However, after accounting for infection, we did not find 
evidence of a protective effect of G6PD A- carriage on maternal anemia risk at delivery. 
 
Birth weight  
One of the most surprising findings was the adverse effect of G6PD A- carriage on 
birth weight.  G6PD A- pregnant women bore infants with low birth weight more frequently 
than G6PD normal women. Furthermore, this difference in risk translated into a large 
difference in mean birth weight.  This is consistent with a previous study in the Gambia in 
which G6PD A- carriage was associated with stillbirths, miscarriages and infertility [21].  
Contrary to expectations, however, G6PD A- carriage of the mother seemed to have a bigger 
impact on reductions in mean birth weight among daughters compared with sons.  It has been 
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hypothesized that a loss in fitness due to G6PD deficiency may be more pronounced for male 
hemizygous carriers and female homozygous carriers, compared to female heterozygotes 
[20].  Most of the G6PD A- carriers in this population of women were heterozygous carriers. 
We would expect 50% of their sons to be hemizygous carriers, and over 50% of daughters to 
be homo- or heterozygous carriers. Given that most female carriers would be heterozygous, 
we would expect to see a larger fitness cost among sons than among daughters. These results 
may also be observed if there was a higher reproductive cost among male hemizygotes and 
female homozygotes, so that female heterozygotes were more likely to survive until delivery.   
A study using mouse models found a higher lethality among female homozygous and male 
hemizygous G6PD deficient fetuses when compared to female heterozygous carriers [22].  
The study also reported significantly lower fetal weight of female homozygous and male 
hemizygous carriers compared with female heterozygotes.  However, female heterozygous 
fetuses also had significantly higher lethality and lower fetal weight compared to G6PD-
normal fetuses.   Additionally, another study conducted in Malawi among neonates found 
that given male gene frequencies for G6PD A- carriage, the gene frequency among females 
was higher than expected [23].  This would also suggest that female heterozygous carriers 
may have a survival advantage in utero compared to male hemizygotes.  To further 
understand our finding in this population, information on neonates’ G6PD status would be 
needed.  Additionally, the range of phenotypic expression of G6PD A- carriage among 
heterozygous carriers in this population could further elucidate this relationship. 
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Limitations 
The interpretation of the results of this study is subject to some limitations. One, 
placental parasitemia was determined through microscopic examination of placental blood 
film instead of histological examination, a more sensitive method [24-26].  This may have 
resulted in misclassification that would have biased the estimates towards the null.  Two, 
unlike the study conducted in Kenya, we did not conduct genetic analyses to detect 
submicroscopic parasitemia. However, parasitemia detectable by microscopy is more likely 
to be clinically relevant. Thirdly, a clearer understanding of the effect of G6PD A- status on 
birth weight would have been aided by information on fathers’ and neonates’ G6PD A- allele 
carriage status. 
These limitations are offset by the strengths of this study. Perhaps the main strength 
of the study is that we were able to determine the effects of G6PD A- carriage on placental 
parasitemia, maternal anemia at delivery and birth weight. To our knowledge, this is the first 
study to do so in the literature.  Secondly, the longitudinal design enabled us to estimate the 
average effect of G6PD A- on malaria parasitemia and anemia over time.  Thirdly, we 
employ appropriate analytic methods taking into account the frequency of the outcome in the 
study population and the special attributes of outcome measures, e.g. longitudinal parasitemia 
risk and semi-continuous parasite density. 
 
Conclusions 
To conclude, we found no clear evidence of protection against malaria parasitemia 
and anemia by G6PD A- status.  Among multigravidae, there was some evidence of minimal 
protection against risk of parasitemia at delivery and high parasite density.  However, in this 
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population of women, G6PD A- carriage was a risk factor for low birth weight, with 
daughters of G6PD A- experiencing the highest reduction in mean birth weight.  More 
studies will be needed to understand the effect of G6PD A- carriage on birth outcomes in 
malaria-endemic areas. 
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Tables 
Table 1. Study Characteristics 
Cases                            
(N=46)
Sub-cohort               
(N= 294)
Full cohort                
(N=831)
Maternal age, mean±SD 22.1 ± 5.0 23.2 ± 5.4 23.4 ± 5.4
Gravidity, %
     Primigravidae 43.5 28.5 28.4
     Multigravidae 56.5 71.5 71.6
Placental parasitemia, % 100.0 15.6 13.4
Peripheral parasitemia at delivery, % 100.0 17.0 13.5
Peripheral parasitemia at enrollment, % 37.0 31.0 30.8
Any parasitemia over follow-up, % 65.2 40.4 41.9
Number of parasitemia episodes over follow-up, %
          0 0.0 53.7 53.4
          1 34.8 25.2 28.5
          ≥2 65.2 21.1 18.1
Report always using bed net, % 17.4 21.4 24.4
Report insecticide treatment of bed net, % 17.4 22.5 22.0
SP doses received, %
          0 6.5 6.5 4.1
          1 26.1 16.7 18.9
          2 32.6 37.4 39.6
          ≥3 34.8 39.5 37.6
HIV infection, % 15.9 13.5 13.5
Anemia at delivery (Hb ≤ 11g/dL), % 26.7 8.8 8.9
Anemia at enrollment (Hb ≤ 11g/dL), % 32.6 20.3 23.2
G6PD A- carrier, % 19.6 27.6
HbS trait, % 6.5 6.1
α-thalassemia, %
        -α/αα 15.2 9.9
        -α/-α 41.3 44.5
Birth weight (mean±SD) 2966 ± 428 3078 ± 503 3056 ± 478
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Table 2.  Parasitemia and low birth weight according to G6PD status and gravidity 
G6PD A-               
% (n/N)         
G6PD normal   
% (n/N)
G6PD A-               
% (n/N)         
G6PD normal   
% (n/N)
G6PD A-               
% (n/N)         
G6PD normal   
% (n/N)
Placental parasitemia 13 (9/69) 17 (37/215) 0.74 (0.36, 1.49) 11 (2/19) 32 (18/56) 0.87 (0.21, 3.61) 14 (7/49) 12 (19/158) 1.21 ( 0.52, 2.81) 0.08
Peripheral parasitemia 19 (13/69) 21 (45/215) 1.03 (0.64, 1.66) 21 (4/19) 34 (19/56) 0.93 (0.43, 1.98) 18 (9/49) 16 (26/158) 1.07 (0.59, 1.95) 0.77
Parasitemia at enrollment 33 (24/73) 27 (61/223) 1.03 (0.87, 1.47) 68 (15/22) 58 (34/59) 1.10 (0.85, 1.42) 18 (9/50) 17 (27/163) 1.01 (0.65, 1.56) 0.49
Any parasitemia over 
follow-up 47 (34/73) 39 (86/223) 1.28 (1.10, 1.56) 77 (17/22) 66 (39/59) 1.16 (0.94, 1.42) 34 (17/50) 29 (47/163) 1.29 (0.96, 1.73) 0.54
Parasitemia ≥ 3 4 (3/73) 9 (21/223) 0.69 (0.34, 1.43) 9 (2/22) 25 (15/59) 0.55 (0.24, 1.27) 2 (1/50) 4 (6/163) 0.81 (0.23, 2.91) 0.62
Average parasitemia risk  
over follow-up 47 (34/73) 39 (86/223) 1.09 (0.74, 1.61) 77 (17/22) 66 (39/59) 0.97 (0.59, 1.57) 34 (17/50) 29 (47/163) 1.16 (0.69, 1.94) 0.62
Low birth weight 21 (11/52) 9 (13/152) 2.47 (1.18, 5.18) 30 (6/20) 11 (4/38) 3.70 (1.37, 9.98) 13 (4/31) 8 (9/113) 2.12 (0.99, 4.56) 0.48
**G6PD A- and gravidity interaction
Prevalence
PR (95%CI)
Interaction     
P-value**     
PR= prevalence ratio, CI=confidence interval
Prevalence*
PR (95% CI)
Prevalence
PR (95% CI)               
Total Primigravidae Multigravidae
* Proportion of case series with trait
 
 
 
Table 3. Parasite density according to visit and G6PD A- status 
Total                                    
ARD (95% CI)
Primigravidae                     
ARD (95% CI)               
Multigravidae               
ARD (95%CI)
Enrollment
         Peripheral 1.48 (0.81, 2.68) 1.38 (0.76, 2.49) 1.56 (0.41, 5.97)
Delivery
         Placental 0.63 (0.23, 1.77) 1.51 (0.29, 7.80) 0.22 (0.08, 0.56)
         Peripheral 0.85 (0.33, 2.16) 1.88 (0.41, 8.65) 0.35 (0.14, 0.85)
ARD = average ratio of densities, CI = confidence interval
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Table 4. Anemia risk according to gravidity and G6PD A- carriage status 
G6PD A-               
% (n/N)         
G6PD normal   
% (n/N)
G6PD A-               
% (n/N)         
G6PD normal   
% (n/N)
G6PD A-               
% (n/N)         
G6PD normal   
% (n/N)
Anemia at delivery 5 (4/77) 10 (20/196) 0.51 (0.18, 1.44) 4 (1/24) 12 (6/49) 0.34 (0.04, 2.67) 6 (3/51) 10 (14/146) 0.61 (0.18, 2.05) 0.62
Anemia at enrollment 17 (13/78) 22 (46/212) 0.78 (0.44, 1.34) 42 (11/26) 29 (16/55) 2.20 (1.27, 3.82) 4 (2/50) 19 (30/156) 0.55 (0.26, 1.18) 0.01
Average parasitemia risk   
over follow-up 30 (23/76) 37 (76/207) 0.78 (0.51, 1.21) 54 (13/24) 52 (28/54) 1.70 (1.00, 2.89) 20 (10/50) 32 (48/152) 0.76 (0.50, 1.16) 0.32
Prevalence Prevalence Prevalence
Multigravidae               
PR (95%CI)
Interaction     
P-value**     
Primigravidae                     
PR (95% CI)               
Total                                    
PR (95% CI)
 
 
 
 
 
Table 5. Effect of mother’s G6PD A- carriage on birth weight according to gender of neonate 
 
Total Primigravidae Multigravidae
Sons
         G6PD A- 19 (6/32) 2.66 (0.88, 8.09) 4 (-205, 197) -149 (-497, 199) 206 (-30, 443)
         Normal 7 (5/71) reference reference reference reference
Daughters
         G6PD A- 25 (5/20) 2.53 (0.93, 6.91) -286 (-529, -42) -319 (-703, 65) -234 (-544, 76)
         Normal 10 (8/81) reference reference reference reference
Mothers' status
LBW          
Prevalence             
LBW                                   
PR (95% CI)
Birth weight  mean difference     (95% CI)
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Figures 
 
 
Figure 1. Mean birth weight according to gravidity and G6PD A- allele carriage status 
 
 
 
 
Figure 2. Mean birth weight according to gender of neonate and G6PD A- allele carriage 
status 
 
 
 
 
  
 
 
 
 
 
CHAPTER SEVEN - DISCUSSION 
 
Summary of findings 
 The purpose of this dissertation was to examine the role of HIV infection and G6PD 
deficiency in malarial parasitemia risk among pregnant women, and the effect of parasitemia 
on adverse pregnancy outcomes.  The research had three main aims. First, we examined the 
separate and joint effects of HIV infection and parasitemia on low birth weight and maternal 
anemia.  Second, we explored the impact of HIV infection on the risk, frequency and severity 
of malaria parasitemia.  Third, we investigated the effect of G6PD A- allele carriage on 
parasitemia, maternal anemia and low birth weight. 
 
HIV, malaria parasitemia, and pregnancy outcomes 
In the first part of this research, we found that HIV infection is associated with 
increased risk of LBW.  Additionally, placental, but not peripheral parasitemia at delivery 
was also associated with increased risk of LBW. However, having three or more episodes of 
peripheral parasitemia over follow-up resulted in an increased risk of LBW.  The results were 
similar for maternal anemia.  Both HIV infection and malaria parasitemia at delivery were 
associated with increased risk of maternal anemia, and the increase in risk was reflected in 
differences in mean hemoglobin levels.  Increasing number of episodes of parasitemia was 
also associated with decreasing hemoglobin levels.   
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Among all women, no interaction between HIV infection and parasitemia were 
observed in their effects on low birth weight and maternal anemia.  However, among 
multigravidae, there was evidence of interaction between HIV infection and parasitemia in 
their effect on low birth weight.  However, this association was not reflected in differences in 
mean birth weight.  There was no evidence of interaction between HIV and parasitemia in 
their effect on maternal anemia. Although having dual infection resulted in the largest 
absolute difference in mean hemoglobin levels, this difference was not more than would be 
expected assuming the effects of HIV infection and parasitemia were independent. 
The finding that both HIV infection and placental parasitemia are associated with 
increased risk of LBW corroborates previous literature [1-3].  Additionally, similar to 
previous literature, we found no evidence of interaction between HIV infection and placental 
parasitemia in their effect on LBW for all women.  However, stratifying by gravidity, there 
was evidence of interaction among multigravidae.  This is not consistent with an earlier study 
in which dual infection with HIV and malaria parasites resulted in a much increased risk of 
LBW relative to single infection only among primigravidae, but not multigravidae [4].  This 
difference could be due to dissimilar impacts of HIV infection on parasitemia according to 
gravidity, examined further in the second section of this research. 
One of the more interesting findings of this research was that frequency of 
parasitemia episodes was associated with increased LBW risk.  To our knowledge, there is 
only one other published study examining the effect of number of episodes of parasitemia on 
birth outcomes.   In the study conducted by Landis and colleagues, having three or more 
episodes of parasitemia over gestation was associated with an increased risk of intrauterine 
growth retardation [5]. Since intrauterine growth retardation can result in low birth weight, 
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these results suggest that frequency of parasitemia episodes has a deleterious impact on birth 
outcomes and should inform how parasitemia is defined in studies examining the effect of 
malaria on the risk of LBW. 
The finding that both HIV infection and parasitemia at delivery are independently 
associated with increased risk of maternal anemia corroborates previous studies[6, 7].  In this 
study, however, we did not find evidence for interaction between HIV and parasitemia in 
their effect on maternal anemia.  This result differs from an earlier study where the joint 
effects of HIV infection and placental parasitemia seemed to indicate synergistic interaction 
between the two infections in their relationship with maternal anemia [4]. However, the 
definition of anemia employed in that study involved a lower cut-off point (Hb<8g/dL). In 
the current study, we rarely observed such profound anemia.  In addition to the different cut-
off for anemia, another reason for the discrepancy may be the multi-factorial nature of 
anemia and its variation from population to population. 
 
Effect of HIV on malaria parasitemia 
In the second part of this research, we report a different effect of HIV on malaria 
parasitemia during follow-up according to gravidity.  Among multigravidae, HIV infection 
was observed to increase the risk of parasitemia throughout the follow-up period. Further, the 
magnitude of this increase in risk was fairly constant at different points during follow-up and 
also averaging over follow-up.  The prevalence and risk of parasitemia observed among HIV-
infected multigravidae was similar to that observed among primigravidae.  Among 
primigravidae, we did not observe a constant effect of HIV on parasitemia, with the 
magnitude of the effect estimates increasing with gestation. Among multigravidae, HIV 
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infection was also associated with a higher frequency of parasitemia episodes.  However, 
among both primigravidae and multigravidae, HIV infection was associated with higher 
parasite peripheral parasite density at delivery and higher placental parasite density. 
We also reported protection by education and malaria preventive behaviors.  At 
enrollment, HIV-infected primigravidae had a lower prevalence of parasitemia than HIV-
uninfected primigravidae.  This was mostly explained by higher educational attainment and 
higher uptake of malaria preventive behaviors by HIV-infected primigravidae when 
compared to their HIV-uninfected counterparts.  Further, low educational attainment 
continued to be a risk factor for parasitemia over the follow-up period for primigravidae.  At 
delivery, reporting nightly use of bed nets was associated with lower peripheral parasite 
densities. Reporting nightly use of bed nets and regular treatment of bed nets with insecticide 
was associated with both lower peripheral and placental parasite densities. 
The finding that HIV infection increases the risk of malaria parasitemia among 
multigravidae to the levels observed among primigravidae corroborates previous literature 
[8-11].  Among primigravidae, we would have expected HIV infection to either increase the 
risk of parasitemiak or to have no effect.  Our results suggest that the effect of HIV infection 
on malaria parasitemia among primigravidae may vary over gestation. However, in this 
population of women there were few HIV infected primigravidae, and the HIV-infected 
primigravidae differed from HIV-uninfected primigravidae in important ways, i.e. higher 
educational attainment and adoption of malaria preventive behaviors.  More longitudinal 
studies will need to be conducted to elucidate the relationship between HIV infection and 
malaria parasitemia over gestation. 
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Few studies report of the effect of HIV infection on frequency of parasitemia 
episodes among pregnant women. However, the findings in the current study confirm the 
results of similar studies among non-pregnant adults [12].  In this study, we found that 
among multigravidae, HIV infection was strongly associated with having 3 or more episodes 
of parasitemia.  We did not observe a similar effect among primigravidae.  This result may 
explain the interaction of HIV infection and parasitemia in their effect on low birth weight 
reported in the first part of this research.  The finding that HIV infection is associated with 
higher parasite densities is also in agreement with previous studies [9, 13, 14]. 
The results of this portion of the dissertation also highlight the effectiveness of 
malaria prevention.  The reduced prevalence of parasitemia among HIV-infected 
primigravidae when compared to HIV-uninfected primigravidae was mostly explained by the 
much higher uptake of malaria preventive behaviors by the former.  Further, reported use of 
bed nets and particularly regular impregnation of bed nets in insecticide was associated with 
lower parasite density at delivery.   
 
Effect of G6PD deficiency on parasitemia and pregnancy outcomes 
In the third part of this research, we investigated the relationship between G6PD 
deficiency, defined as carriage of the G6PD A- allele, malaria parasitemia and pregnancy 
outcomes.  We did not find evidence of protection against malaria parasitemia and maternal 
anemia by carriage of the G6PD A- allele.  However, among multigravidae, carriage of the 
G6PD A- allele was associated with lower peripheral parasite density at delivery and lower 
placental parasite density. Additionally, among multigravidae, there was some suggestion of 
protection against maternal anemia by G6PD A- deficiency. Among primigravidae, G6PD A- 
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deficiency was associated with an increased risk of maternal anemia at enrollment and 
averaging over follow-up. 
Among both gravidities, however, we found that carriage of the G6PD A- allele was 
strongly associated with LBW.  Further, this translated into a large difference in mean birth 
weight among G6PD A- mothers compared to G6PD normal mothers.  While the risk of 
LBW was elevated for both sons and daughters of mothers carrying the G6PD A- allele, a 
large reduction in mean birth weight was only observed for daughters. 
There is only one other study in the literature reporting the effect of carriage of G6PD 
A- deficiency on parasitemia and anemia risk among pregnant women [15].  After calculating 
prevalence ratios from the data presented in the study, the effect estimates of the effect of 
G6PD A- deficiency on malaria parasitemia and maternal anemia among multigravidae were 
similar to those reported in the current study.  The finding that G6PD A- deficiency among 
primigravide was associated with higher risk of maternal anemia may be due to infection 
induced hemolyis, since primigravidae are at higher risk of malaria parasitemia compared to 
multigravidae.   
Although we did not find a strong protective effect of G6PD A- deficiency on 
parasitemia at delivery, among multigravidae, G6PD A- deficiency was strongly associated 
with lower parasite density. This may be due to the combination of gravidity-dependent 
immunity reducing adhesion of infected erythrocytes, and G6PD A- deficiency-mediated 
inhibition of parasite growth and enhanced phagocytosis of infected cells [16-20]. In vitro 
studies will need to be conducted to understand how malaria parasites interact with G6PD A- 
deficient erythrocytes in the placental circulation. 
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Perhaps the most novel finding of this research was the increased risk of LBW due to 
G6PD A- deficiency.  A previous study has reported adverse obstetric outcomes, such as 
miscarriage and stillbirth associated with G6PD A- deficiency [21].  Further, G6PD 
deficiency has been hypothesized to reduce fitness of affected individuals.  However, 
contrary to expectations, we found a larger reduction in mean birth weight among daughters 
of G6PD A- deficient mothers.  This may signify that there is a greater reproductive cost 
among male hemizygous and female homozygous carriers, so that female heterozygous 
carriers are born alive more frequently, albeit with reduced fitness.  This is in agreement with 
the results of a study conducted using mice models in which female homozygous and male 
hemizygous fetuses exhibited higher lethality and lower fetal weight than female 
heterozygous carriers and a survey conducted in southern Malawi among neonates in which 
the gene frequency for female heterozygous carries of the G6PD A- allele was higher than 
would be expected given the gene frequency among males [22, 23]. 
 
Conclusions 
 
The results of this research underscore the importance of targeted interventions to 
improve pregnancy outcomes among women living in malaria-endemic areas. In this study 
we report adverse effects of frequency of parasitemia episodes on low birth weight.  Further, 
we report increased risk and frequency of parasitemia due to HIV infection among 
multigravidae.  Recent studies suggest that the current regimen of IPTp may not be effective 
in reducing malaria and improving pregnancy outcomes among HIV-infected women [24, 
25].  The reduced effectiveness of prophylactic drugs should highlight the need for continued 
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attention to malaria prevention behaviors such as use of insecticide-treated bed nets.  In the 
current research, we report the effectiveness of malaria preventive behaviors in reducing risk, 
frequency and severity of parasitemia. However, an integrated approach that involves both 
preventive behaviors and anti-malaria prophylaxis would be maximally beneficial in 
improving pregnancy outcomes.  More research will need to be conducted to determine the 
most optimal dosing strategies for women of all gravidities, and to find alternative 
prophylactic regimens in the face of increasing resistance. 
The search for alternative anti-malarial drugs must necessarily be informed by the 
frequency and effects of G6PD deficiency in malaria-endemic countries.  In this study we 
report a high prevalence of G6PD deficiency among Malawian women.  Further, we report 
the lack of a protective effect of G6PD deficiency of parasitemia, and maternal anemia risk.  
Additionally, we report increased risk of LBW due to G6PD A- deficiency. Future research 
will be needed to further understand the relationship between G6PD A- deficiency and birth 
outcomes. 
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APPENDICES 
 
 APPENDIX A – Informed Consent 
 
1. CHIPHASO CHOLOLEDZA – AMAYI APAKATI  
 
Tikukupemphani kuti mutenge nawo mbali mukafukufukuyu. Kutenga mbali kwanu  ndi kwa ufulu. 
Simuyenera kuvomereza kupanga nawo kuti mulandire chisamaliro, ndikuti muudzabelekere pa 
chipatala chino. Mutasintha maganizo, mutha kusiya nthawi iliyonse popanda chovuta chilichonse 
 
Matenda a malungo nthawi yomwe mai ali oyembekezera angathe kuononga umoyo wa mwana wake. 
Pachifukwa ichi, boma la Malawi limalangiza kuti mzimayi aliyense woyembekezera alandire 
makhwala otetezera malungo. Mogwirizana ndi sukulu ya University ya North Carolina, ife tikufuna 
kufufuza kuti tione ngati malangizowo akugwiradi ntchito. Kafukufukuyu adzathandiza kupeza 
malangizo oyenerera opewera matenda a malungo, mtsogolomu.   
 
Ngati muvomereza kulowa kafukufukuyu anamwino adzatenga timagazi pang’ono, kuti akayeze ngati 
muli ndi malungo, chindoko, kapenanso kuchepa kwa magazi. Magazi onse adzatengedwa ndi 
zoyezera ndi zobayila zatsopano. Nthawi zina pangaoneke kabala (kachilonda) kakang’ono pamalo 
pomwe patengedwa magazi. Anamwino adzakuyezani sikelo ndikukufunsani mafunso angapo. 
Mutapezeka ndi malungo kapena chindoko, mudzapatsidwa mankhwala oti akuchiritseni. Mukadali 
oyembekezela chomwechi, mudzafunsidwa kukaunikidwa mwezi ndi mwezi kuti tione kuti mwana 
akukula bwanji. Mukadzabereka, tidzamuyezanso mwana wanu, ndi kutenga timagazi pang’ono 
kuchokela pa nchombo, ndi pa nsengwa ya mwana kukayezanso malungo. Ndondomeko yonse 
kuchokera pa ulendo woyambawu, ndi maulendo otsatira ndikubereka mwana wanu zidzaikidwa 
m’mabukhu achinsinsi, ndi kufufuzidwa bwino. 
   
Kuonjezera apa tidzakufunsani ngati mungafune kuti mudziwe ngati muli ndi kachilombo ka HIV. 
Ngati mudzalore kuyezedwa, tidzakulongosolerani zonse zokhudzana ndi kuyeza kwa kachilombo ka 
HIV tisanatenge magaziwa. Tidzakudziwitsani zotsatira zake, ndipo tizakambirana nanu kutanthauza 
kwa zotsalirazi pamoyo wanu ndi banja lanu. Zonsezi zidzachitika mwachinsinsi, ndipo ndi inu nokha 
osati wina aliyense yemwe atazadziwe zotsatira za zomwe mwayezedwa. Muli ololedwa kukhala 
nawo mukafukufukuyi ngakhale mutakhala kuti simukufuna kuti tikuyezeni matenda a HIV. 
Tikadzakupezani ndi matenda a HIV, inu ndi mwana wanu akangobadwa kumene mudzapatsidwa 
 110 
 
 
 
 
  
makhwala otchedwa nevirapine omwe amateteza theka la ana omwe anakatenga kachilombo ka HIV 
kuchokera kwa mai awo. Nthawi ino sitingathe kukupatsani mankhwala a HIV koma tizakuthandizani 
kuti mudzalandire mankhwalawa mwamsanga akazapezeka ku unduna wa zaumoyo ndi chiwerengelo 
cha anthu. 
 
Tikutsimikiza kuti tidzasunga mapepala anu onse a zotsatira zonse zamukafukufukuyi mwa chimsisi 
ndipo palibe wina aliyense yemwe azathe kudziwa dzina lanu kuchokera pa mapepalawa.  Mapepala 
anu onse tidzasunga pamalo obisika mu kabati ya chitsulo yomwe tidzizatsekamo ndi kiyi poti wina 
aliyense sazatha kupeza zotsatirazi.   
 
Ngati muli ndi mafunso apadera 
 
Ngati muli ndi mafunso pankhaniyi ngakhale zina zonse zokhuzana ndi kafukufukuyu, kapena 
chobvuta chili chonse chingabwere chifukwa chakafukufukuyi muyankhule ndi anthu awa pamaso 
ngakhale pa telefoni; 
 
Mr I. Mofolo  Telefoni  01671911 kapena 09957678 
Mrs E. Chaluluka Telefoni 01671911 kapena 08308339 
 
Kodi mukuvomereza kulowa kafukufukuyu? 
 
Kuvomeredza 
Ine ndawerenga/ndamva zonse zimene zalembedwazi ndipo ndamvetsa tanthauzo la zinthu zimenezi. 
Choncho ndavomera kuti ndikhale mmodzi mwa anthu omwe atenge nawo mbali mu kafukufuku uyu. 
 
Chitsimikizo ............................................................. Tsiku_____/____/____ 
 
 
Chidindo cha chala:………………………………… 
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APPENDIX B – Protocol/Instruments 
 
NEW MALARIA IN PREGNANCY STUDY 
SOP version 14 March 2005 
 
DESCRIPTION 
A study of pregnant women to look at the effects of malaria, SES and HIV on 
birth weight and maternal haemoglobin.  
 
STUDY PARTICIPANTS 
All pregnant women (14-26 weeks) at 1st antenatal visit in Mpemba and 
Madziabango. 
 
ENROLLMENT PROCEDURE 
1st VISIT 
1. Identify pregnant women between 14 – 26 weeks of gestation at their first 
ANC visit 
2. Administer VCT including counseling and rapid tests 
3.  Fill in VCT proforma 
4. Obtain informed consent 
5. Assign study number and write it on all proformas 
6. Place identity sticker on health passport 
7. Take relevant history; medical and obstetric 
8. Physical examination: BP, weight and height 
9. Lab tests: malaria, hemocue, syphilis, temperature 
10. Administer SP (DOT), Folate and Iron 
11. Fill in Enrollment proforma make a patient folder 
12. Fill in SES proforma 
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ALL SUBSEQUENT VISITS 
1. ANC Visit proforma 
2. Physical examination 
3. Administer SP if >4 weeks since 1st dose + Folate and Iron if needed 
4. VCT if didn’t consent during the 1st visit 
5. Lab tests:  malaria and hemocue 
 
Other visits: 
1. Fill in a new ANC follow up proforma for each additional visit 
2. Do malaria tests and hemocues 
 
DELIVERY 
During labour 
1.     Administer nevirapine to HIV positive moms only 
 
At delivery 
2. Lab tests – malaria smears on mother and placenta;  Hemocue on mother 
3. Measure baby’s birth weight and Ballard score 
4. Delivery information – mother proforma 
5. Delivery information – baby proforma 
Administer nevirapine to babies of HIV-positive mothers and fill in nevirapine 
proforma
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VCT Proforma 
                                                                                                                                           
Agreed to VCT 
    Yes             No 
 
Pre-test counseling 
 
Given by      
 
Initials    Date     
 
Test results 
Determine  …….  Initials/Date     
Unigold   ………  Initials/Date     
Hema-Strip ……  Initials/Date     
1= positive 
2=negative 
3= indeterminate 
4= not done 
 
Post-test counseling 
Given by      
Initials    Date     
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Enrollment  Proforma 
 
IS THIS THE PATIENT’S FIRST VISIT? YES/NO Visit date __/__/____ 
If yes, proceed 
 
Name __________________________ Age _____ Gravidity _______ 
Weeks pregnant _________ Determined by:   dates/ palpation 
Residence location _________________ 
 
Malaria history 
Prior antimalarials during this pregnancy? Yes/No If yes, number of doses _____ 
Recent fever (in past week)?   Yes/No 
Net user? (circle appropriate answer) 1 Never 2 Sometimes 3 Usually 4 Always 
Net impregnated? 1 Never 2 > 6 mos. 3 within 6 mos. 4 Don’t know 
 
Physical exam/labs 
Maternal height _____cm Maternal weight ____.___ kg 
Mother’s HemoCue _____g/dl  
Syphilis rapid test result             positive/negative           Treatment given  yes/no 
Temperature at clinic _________ 
Peripheral film 0 + ++ +++ ++++ Peripheral count __________ 
 
Procedures 
Study number assigned?  Enter on all proformas 
SP given at this visit? Yes/No Administered how? DOT Take home Unknown 
Filter paper made and numbered?   Yes  No 
 
 
Obstetric or medical complications 
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SES Profoma 
 
 
1. INFORMATION ON PARTICIPANT 
 
Age of mother (years) .......................................................................................... I__I__I 
    
What is the highest level of schooling you have had  (circle) 0=none 
  1=standard 1-4
  
  2=standard 5-8 
  3=form 1-2 
  4=form 3-4 
  5=university 
 
2. INFORMATION ON COMPOSITION OF HOUSEHOLD  
 
Total number of persons in household (people who normally eat together) ...................... I__I__I 
 
Total number of children in household  ............................................................................ I__I__I 
 
 
What is mother's marital status? .......... 1 = Married with husband in the household 
  2 = Single 
  3 = Divorced or separated 
  4 = Widowed 
  9 = Not known  
 
3. INFORMATION ON FAMILY INCOME AND ECONOMIC STATUS  
 
What do you do?  1 working for wages 
 2 selling items 
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 3 none 
 9 not known    
  
What does your husband do?  1 working for wages 
 2 selling items 
 3 none 
 9 not known 
 
Does your family earn enough to meet its needs for the year? 
  1 Yes 
 2. No 
  
Does your family have a steady (regular) source of income over the year? 
  1 Yes 
 2. No 
   
Does the household possess a 
 
 
Yes No 
Mattress   
Radio   
Bicycle   
Car   
 
 
4. INFORMATION ON HOUSING  
  
What is the building material of the walls of the main house?............. 1 = Poles and grass 
  2 = Poles and mud 
 If other, please specify ______________________________ 3 = Mud 
  4 = Mud brick 
  5 = Fired brick 
  8 = Other 
  9 = Not known 
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What is the building material of the roof of the main house? .............. 1 = Grass 
  2 = Iron sheets 
 If other, please specify ______________________________ 3 = Tiles 
  8 = Other 
  9 = Not known 
    
What kind of windows does the main house have? ............................ 0 = None 
  1 = Open windows 
 If other, please specify ______________________________ 2 = Screen or glass 
  8 = Other 
  9 = Not known  
   
What is the source of drinking water? ................................................ 1 = Piped water 
  2 = Borehole 
 If other, please specify _______________________________ 3 = Protected well 
   4 = Unprotected well 
  5 = Lake 
  6 = River, pond 
  8 = Other 
  9 = Not known   
 
Sanitary facilities ................................................................................ 0 = None 
  1 = Ventilated improved pit latrine 
 If other, please specify _______________________________ 2 = Regular pit latrine 
  8 = Other 
  9 = Not known  
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(PLEASE FILL OUT A NEW SEPARATE SHEET FOR EACH VISIT) 
 
ANC Visit Proforma 
 
Visit date ___/___/______  
Name __________________________ Age _____ Gravidity _____ 
Visit number ______Weeks pregnant ____ Determined by dates estimated palpation 
Antimalarials since last visit? Yes/No 
Peripheral film 0 + ++ +++ ++++ Peripheral count _____________________ 
Recent fever (past 7 days)  Yes/No 
Temperature at clinic _____________ 
 
SP given at this visit? Yes/No Administered how? DOT Take home Unknown 
 
Other medications given (such as quinine)?  Please give drug and dosage. 
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Delivery information - Mother 
 
1. DELIVERY 
 
Date and time of delivery  _________ 
Place of delivery:  ................................1 = Home  
  2 = TBA facility 
 If other, please specify: ______________________________ 3 = Health centre 
   4 = District or CHAM 
          hospital 
   5 = Central hospital 
   8 = Other 
  9 = Not known 
Attendant during delivery  ...............................................................0 = None 
 1 = TBA 
  2 = Friend, relative or other 
 3 = Nurse / midwife 
 4 = Ward attendant 
 5 = Clinical officer 
 6 = Doctor 
 9 = Not known 
Duration of delivery: ........................................................................1 = Less than 12 hours 
 2 =  12 -24 hours 
 3 = More than 24 hours 
Number of children born: _______________________________ 
Presentation of child: ......................................................................1 = Breach 
 2 = Vertex 
If other, please specify: _____________________________ 3 = Feet 
 4 = Hands 
 5 = Cord 
 6 = Face 
 8 = Other 
 9 = Not known 
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Mode of delivery:..................................................................... 1 = Normal vaginal 
2 = Normal vaginal with large perineal tear 
3 = Elective caesarean section 
4 = Emergency caesarean section 
5 = Forcep  
6 = Vacuum extraction 
8 = Other                                   If other, please specify: _______________________ 
9 = Not known  
      
Were there any delivery complications? ................................. 0 = No 
 1 = Yes 
  
If yes, please describe: 
 
 
 
Were you referred to a health centre or a hospital? ..................   0 = No 
 If yes, reason: ________________________________________ 1 = Yes 
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Physical exam/Lab results 
 
Fever in week before delivery   Yes/no 
Fever at delivery  Yes/no  (Take temperature if in clinic) 
Fever after delivery  Yes/No    
Blood pressure ______________  
Hemocue     
Maternal peripheral parasitemia film 0 + ++ +++ ++++      
     count _____________________ 
Placental parasitemia film   0 + ++ +++ ++++     count _____________________   
 
Filter paper taken?  Yes/no       
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Delivery Information on Newborn 
 
 
Date of birth ___/___/___          Date child seen ___/___/___ 
Age of child when seen  (Days)  ..................................................................... ______ 
Was the child born alive? ................................................................................ 0 = No 
  1 = Yes 
If no, type of stillbirth ....................................................................................... 1 = 
Fresh 
 2 = 
Macerated  
Sex of the child ............................................................................................... 1 = Girl 
  2 = Boy 
Child's size at birth:  
 Weight (g) I__I__I__I__I 
 Length (mm) I__I__I__I 
 Chest circumference (mm) I__I__I__I 
 Head circumference (mm) I__I__I__I 
 Mid upper-arm circumference (mm) I__I__I__I 
Ballard (0 – 4/5 points each): 
  Points: 
Skin  
Lanugo  
Plantar creases  
Breast  
Ear  
Genitals  
Total:  
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Nevirapine proforma 
 
Nevirapine tablet (200 mg) to mother 
 
Given by      
 
Initials    Time     Date     
 
Nevirapine syrup (0.2 ml per kg) to baby 
 
Given by      
 
Initials    Time     Date     
 
 
 
 
 
 
